<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antibody induction therapy for lung transplant recipients - Penninga, L - 2013 | Cochrane Library</title> <meta content="Antibody induction therapy for lung transplant recipients - Penninga, L - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008927.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antibody induction therapy for lung transplant recipients - Penninga, L - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008927.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008927.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Antibody induction therapy for lung transplant recipients" name="citation_title"/> <meta content="Luit Penninga" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="LP@ctu.dk" name="citation_author_email"/> <meta content="Christian H Møller" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Elisabeth I Penninga" name="citation_author"/> <meta content="Bispebjerg Hospital" name="citation_author_institution"/> <meta content="Martin Iversen" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Christian Gluud" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Daniel A Steinbrüchel" name="citation_author"/> <meta content="Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD008927.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/11/27" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008927.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008927.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008927.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Lung Transplantation; Alemtuzumab; Antibodies, Monoclonal [therapeutic use]; Antibodies, Monoclonal, Humanized [therapeutic use]; Antilymphocyte Serum [therapeutic use]; Basiliximab; Daclizumab; Graft Rejection [immunology, *prevention &amp; control]; Immunoglobulin G [therapeutic use]; Immunosuppression Therapy [adverse effects, *methods]; Immunosuppressive Agents [adverse effects, *therapeutic use]; Muromonab‐CD3 [therapeutic use]; Randomized Controlled Trials as Topic; Receptors, Interleukin‐2 [antagonists &amp; inhibitors]; Recombinant Fusion Proteins [therapeutic use]; T‐Lymphocytes [*immunology]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008927.pub2&amp;doi=10.1002/14651858.CD008927.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="cdmLYOAV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008927\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008927\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008927\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008927\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008927.pub2",title:"Antibody induction therapy for lung transplant recipients",firstPublishedDate:"Nov 27, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Kidney and Transplant Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008927.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008927.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008927.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008927.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008927.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008927.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008927.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008927.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008927.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008927.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1009 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008927.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#CD008927-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#CD008927-sec-0131"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#CD008927-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#CD008927-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#CD008927-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#CD008927-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#CD008927-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#CD008927-sec-0125"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/appendices#CD008927-sec-0136"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/table_n/CD008927StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/table_n/CD008927StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antibody induction therapy for lung transplant recipients</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/information#CD008927-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Luit Penninga</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/information#CD008927-cr-0003">Christian H Møller</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/information#CD008927-cr-0004">Elisabeth I Penninga</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/information#CD008927-cr-0005">Martin Iversen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/information#CD008927-cr-0006">Christian Gluud</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008927.pub2/information#CD008927-cr-0007">Daniel A Steinbrüchel</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/information/en#CD008927-sec-0140">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 27 November 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008927.pub2">https://doi.org/10.1002/14651858.CD008927.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008927-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008927-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008927-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008927-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008927-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008927-abs-0001" lang="en"> <section id="CD008927-sec-0001"> <h3 class="title" id="CD008927-sec-0001">Background</h3> <p>Lung transplantation has become a valuable and well‐accepted treatment option for most end‐stage lung diseases. Lung transplant recipients are at risk of transplanted organ rejection, and life‐long immunosuppression is necessary. Clear evidence is essential to identify an optimal, safe and effective immunosuppressive treatment strategy for lung transplant recipients. Consensus has not yet been achieved concerning use of immunosuppressive antibodies against T‐cells for induction following lung transplantation. </p> </section> <section id="CD008927-sec-0002"> <h3 class="title" id="CD008927-sec-0002">Objectives</h3> <p>We aimed to assess the benefits and harms of immunosuppressive T‐cell antibody induction with ATG, ALG, IL‐2RA, alemtuzumab, or muromonab‐CD3 for lung transplant recipients. </p> </section> <section id="CD008927-sec-0003"> <h3 class="title" id="CD008927-sec-0003">Search methods</h3> <p>We searched the Cochrane Renal Group's Specialised Register to 4 March 2013 through contact with the Trials Search Co‐ordinator using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE and EMBASE. </p> </section> <section id="CD008927-sec-0004"> <h3 class="title" id="CD008927-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) that compared immunosuppressive monoclonal and polyclonal T‐cell antibody induction for lung transplant recipients. An inclusion criterion was that all participants must have received the same maintenance immunosuppressive therapy within each study. </p> </section> <section id="CD008927-sec-0005"> <h3 class="title" id="CD008927-sec-0005">Data collection and analysis</h3> <p>Three authors extracted data. We derived risk ratios (RR) for dichotomous data and mean differences (MD) for continuous data with 95% confidence intervals (CI). Methodological risk of bias was assessed using the Cochrane risk of bias tool and trial sequential analyses were undertaken to assess the risk of random errors (play of chance). </p> </section> <section id="CD008927-sec-0006"> <h3 class="title" id="CD008927-sec-0006">Main results</h3> <p>Our review included six RCTs (representing a total of 278 adult lung transplant recipients) that assessed the use of T‐cell antibody induction. Evaluation of the included studies found all to be at high risk of bias. </p> <p>We conducted comparisons of polyclonal or monoclonal T‐cell antibody induction versus no induction (3 studies, 140 participants); polyclonal T‐cell antibody versus no induction (3 studies, 125 participants); interleukin‐2 receptor antagonists (IL‐2RA) versus no induction (1 study, 25 participants); polyclonal T‐cell antibody versus muromonab‐CD3 (1 study, 64 participants); and polyclonal T‐cell antibody versus IL‐2RA (3 studies, 100 participants). Overall we found no significant differences among interventions in terms of mortality, acute rejection, adverse effects, infection, pneumonia, cytomegalovirus infection, bronchiolitis obliterans syndrome, post‐transplantation lymphoproliferative disease, or cancer. </p> <p>We found a significant outcome difference in one study that compared antithymocyte globulin versus muromonab‐CD3 relating to adverse events (25/34 (74%) versus 12/30 (40%); RR 1.84, 95% CI 1.13 to 2.98). This suggested that antithymocyte globulin increased occurrence of adverse events. However, trial sequential analysis found that the required information size had not been reached, and the cumulative Z‐curve did not cross the trial sequential alpha‐spending monitoring boundaries. </p> <p>None of the studies reported quality of life or kidney injury. Trial sequential analyses indicated that none of the meta‐analyses achieved required information sizes and the cumulative Z‐curves did not cross the trial sequential alpha‐spending monitoring boundaries, nor reached the area of futility. </p> </section> <section id="CD008927-sec-0007"> <h3 class="title" id="CD008927-sec-0007">Authors' conclusions</h3> <p>No clear benefits or harms associated with the use of T‐cell antibody induction compared with no induction, or when different types of T‐cell antibodies were compared were identified in this review. Few studies were identified that investigated use of antibodies against T‐cells for induction after lung transplantation, and numbers of participants and outcomes were also limited. Assessment of the included studies found that all were at high risk of methodological bias. </p> <p>Further RCTs are needed to perform robust assessment of the benefits and harms of T‐cell antibody induction for lung transplant recipients. Future studies should be designed and conducted according to methodologies to reduce risks of systematic error (bias) and random error (play of chance). </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008927-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008927-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008927-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008927-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008927-abs-0005">Français</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008927-abs-0004" lang="en"> <h3>Can antibody induction therapy help to reduce organ rejection for lung transplant recipients? </h3> <p>People who receive transplanted lungs are at significant risk of organ rejection. To help reduce the risk of organ rejection, antibodies against T‐cells (a type of white blood cell that plays a central role in immunity) are given to patients within the first two weeks after transplantation. Several types of antibodies have been used, but their benefits and harms are unclear. </p> <p>We evaluated the use of antibodies against T‐cells following lung transplantation to find out whether this therapy was safe, beneficial or harmful, and which type of antibodies work best with fewest adverse effects. </p> <p>We analysed six studies that investigated the use of several different types of antibody therapies in 278 adult patients following lung transplantation. Flaws in study designs were found that indicated the studies were at risk of overestimating benefits and underestimating harms. </p> <p>Our analysis compared several types of antibodies, but with one exception ‐ that antithymocyte globulin seemed to increase some adverse events ‐ we found no significant differences in lung survival or rejection for any of the treatments. There was some uncertainty about this effect because the study was too small to be sure that observed benefits would apply to a larger population. We found no significant differences among therapies in terms of infection, bronchiolitis obliterans syndrome, post‐transplantation lymphoproliferative disease, or cancer. </p> <p>Few investigated the use of T‐cell antibodies after lung transplantation, and these included small numbers of participants. These limitations meant that our findings did not necessarily indicate no differences existed among comparisons in our analysis. To overcome this problem, larger and more robust randomised studies that assess the benefits and harms of antibodies against T‐cells for people following lung transplantation are needed. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008927-sec-0131" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008927-sec-0131"></div> <h3 class="title" id="CD008927-sec-0132">Implications for practice</h3> <section id="CD008927-sec-0132"> <p>Recognising the limitations of the review relating to the size and nature of the included studies, our systematic review did not show any clear beneficial or harmful effects associated with the use of antibody induction therapy regarding mortality, acute rejection, infection, pneumonia, cytomegalovirus infection, bronchiolitis obliterans syndrome, PTLD or cancer. When trial sequential analyses were conducted on the primary outcome measures of mortality and acute rejection, the required information size was not obtained for any of the comparisons. </p> </section> <h3 class="title" id="CD008927-sec-0133">Implications for research</h3> <section id="CD008927-sec-0133"> <p>Given the result of our analysis, it appears warranted that appropriately sized and powered randomised studies comparing T‐cell antibodies versus placebo in lung transplant patients using contemporarily adjunctive immunosuppression be undertaken. These studies should investigate interventions using basiliximab (currently the only IL‐2RA commercially available), ATG, or alemtuzumab. Such studies should be designed and conducted to achieve low risks of systematic error (bias) and random error (play of chance), and should follow the CONSORT guidelines. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008927-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008927-sec-0022"></div> <div class="table" id="CD008927-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">T‐cell antibody induction compared with no antibody induction for lung transplant recipients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>T‐cell antibody induction compared with no antibody induction for lung transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> lung transplant recipients<br/> <b>Settings:</b> patients with end‐stage lung failure who underwent lung transplantation<br/> <b>Intervention:</b> antibody induction<br/> <b>Comparison:</b> no antibody induction </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> No antibody induction</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Antibody induction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b> <br/> Follow‐up: 2 to 8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.99</b> <br/> (0.69 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>140 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>448 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>444 per 1000</b> <br/> (309 to 632) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>396 per 1000</b> <br/> (276 to 564) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Acute rejection grade II or higher</b> <br/> Follow‐up: 2 to 8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.66</b> <br/> (0.43 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>140 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>483 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>319 per 1000</b> <br/> (208 to 492) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>330 per 1000</b> <br/> (215 to 510) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Infection</b> <br/> Follow‐up: 2 to 8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.4</b> <br/> (0.97 to 2.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>104 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>458 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>642 per 1000</b> <br/> (445 to 921) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>458 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>641 per 1000</b> <br/> (444 to 921) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Bronchiolitis obliterans syndrome</b> <br/> Follow‐up: 2 to 8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.77</b> <br/> (0.55 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>140 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>534 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>412 per 1000</b> <br/> (294 to 583) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b> <br/> (220 to 436) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ All studies were assessed to be at high risk of bias using the Cochrane risk of bias tool </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008927-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Polyclonal T‐cell antibody compared with no antibody induction for lung transplant recipients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Polyclonal T‐cell antibody compared with no antibody induction for lung transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> lung transplant recipients<br/> <b>Settings:</b> patients with end‐stage lung disease who underwent lung transplantation<br/> <b>Intervention:</b> polyclonal antibody<br/> <b>Comparison:</b> no antibody induction </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> No antibody induction</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Polyclonal antibody</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b> <br/> Follow‐up: 2 to 8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.02</b> <br/> (0.71 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>125 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>448 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>457 per 1000</b> <br/> (318 to 659) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>408 per 1000</b> <br/> (284 to 588) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Acute rejection grade II or higher</b> <br/> Follow‐up: 2 to 8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.68</b> <br/> (0.44 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>125 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>483 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>328 per 1000</b> <br/> (212 to 502) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>340 per 1000</b> <br/> (220 to 520) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Infection</b> <br/> Follow‐up: 2 to 8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.4</b> <br/> (0.97 to 2.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>104 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>458 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>642 per 1000</b> <br/> (445 to 921) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>458 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>641 per 1000</b> <br/> (444 to 921) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Bronchiolitis obliterans syndrome</b> <br/> Follow‐up: 2 to 8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.81</b> <br/> (0.57 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>125 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>534 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>433 per 1000</b> <br/> (305 to 620) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>324 per 1000</b> <br/> (228 to 464) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ All studies were assessed to be at high risk of bias using the Cochrane risk of bias tool </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008927-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">IL‐2 receptor antagonist induction compared with no antibody induction for lung transplant recipients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>IL‐2 receptor antagonist induction compared with no antibody induction for lung transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> lung transplant recipients<br/> <b>Settings:</b> patients with end‐stage lung disease who underwent lung transplantation<br/> <b>Intervention:</b> interleukin‐2 receptor antagonist (IL‐2RA) induction<br/> <b>Comparison:</b> no antibody induction </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> No antibody induction</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> IL‐2RA induction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b> <br/> Follow‐up: mean 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.67</b> <br/> (0.22 to 2.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>25 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b> <br/> (88 to 828) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b> <br/> (88 to 828) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Acute rejection</b> <br/> Follow‐up: mean 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.07</b> <br/> (0.49 to 2.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>25 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>535 per 1000</b> <br/> (245 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>535 per 1000</b> <br/> (245 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Bronchiolitis obliterans syndrome</b> <br/> Follow‐up: mean 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.33</b> <br/> (0.07 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>25 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b> <br/> (28 to 596) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b> <br/> (28 to 596) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ All studies were assessed to be at high risk of bias using the Cochrane risk of bias tool </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008927-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Polyclonal T‐cell antibody induction compared with interleukin‐2 receptor antagonist induction for lung transplant recipients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Polyclonal T‐cell antibody induction compared with IL‐2RA induction for lung transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> lung transplant recipients<br/> <b>Settings:</b> patients with end‐stage lung disease who underwent lung transplantation<br/> <b>Intervention:</b> polyclonal antibody induction<br/> <b>Comparison:</b> interleukin‐2 receptor antagonist (IL‐2RA) induction </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> IL‐2RA induction</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Polyclonal antibody induction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b> <br/> Follow‐up: 0.5 to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.41</b> <br/> (0.55 to 3.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>100 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>113 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> <br/> (62 to 412) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b> <br/> (42 to 280) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Acute rejection</b> <br/> Follow‐up: 1 to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.33</b> <br/> (0.93 to 1.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>76 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>525 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>698 per 1000</b> <br/> (488 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>527 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>701 per 1000</b> <br/> (490 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Infection</b> <br/> Follow‐up: mean 1 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.91</b> <br/> (0.71 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>50 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>880 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>801 per 1000</b> <br/> (625 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>880 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>801 per 1000</b> <br/> (625 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Bronchiolitis obliterans syndrome</b> <br/> Follow‐up: 1 to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.66</b> <br/> (0.42 to 6.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>76 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>124 per 1000</b> <br/> (31 to 490) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>144 per 1000</b> <br/> (37 to 568) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ All studies were assessed to be at high risk of bias using the Cochrane risk of bias tool </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008927-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008927-sec-0023"></div> <section id="CD008927-sec-0024"> <h3 class="title" id="CD008927-sec-0024">Description of the condition</h3> <p>Success in lung transplantation has led to wide acceptance of the procedure as a treatment for most end‐stage lung diseases. Over 30,000 lung transplantations have been reported to the International Society for Heart and Lung Transplantation (<a href="./references#CD008927-bbs2-0025" title="ChristieJD , EdwardsLB , KucheryavayaAY , BendenC , DobbelsF , KirkR , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐eighth Adult Lung and Heart‐Lung Transplant Report‐‐2011. Journal of Heart &amp; Lung Transplantation2011;30(10):1104‐22. [MEDLINE: 21962018] ">Christie 2011</a>); and of the more than 2700 lung transplantations reported annually, one year survival is over 80%, and five year survival is 60% (<a href="./references#CD008927-bbs2-0021" title="AuroraP , EdwardsLB , ChristieJD , DobbelsF , KirkR , RahmelAO , et al. Registry of the international society for heart and lung transplantation: twelfth official pediatric lung and heart/lung transplantation report‐2009. Journal of Heart &amp; Lung Transplantation2009;28(10):1023‐30. [MEDLINE: 19782284] ">Aurora 2009</a>; <a href="./references#CD008927-bbs2-0025" title="ChristieJD , EdwardsLB , KucheryavayaAY , BendenC , DobbelsF , KirkR , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐eighth Adult Lung and Heart‐Lung Transplant Report‐‐2011. Journal of Heart &amp; Lung Transplantation2011;30(10):1104‐22. [MEDLINE: 21962018] ">Christie 2011</a>). </p> <p>Long‐term recipient survival after lung transplantation remains suboptimal, mainly due to occurrence of bronchiolitis obliterans syndrome. Bronchiolitis obliterans syndrome and late graft failure are responsible for more than 40% of deaths beyond the first year of transplantation (<a href="./references#CD008927-bbs2-0025" title="ChristieJD , EdwardsLB , KucheryavayaAY , BendenC , DobbelsF , KirkR , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐eighth Adult Lung and Heart‐Lung Transplant Report‐‐2011. Journal of Heart &amp; Lung Transplantation2011;30(10):1104‐22. [MEDLINE: 21962018] ">Christie 2011</a>). Primary risks for developing bronchiolitis obliterans syndrome are acute rejection and lymphocytic bronchitis (<a href="./references#CD008927-bbs2-0035" title="HollmenM , TikkanenJM , NykanenAI , KoskinenPK , LemstromKB . Tacrolimus treatment effectively inhibits progression of obliterative airway disease even at later stages of disease development. Journal of Heart &amp; Lung Transplantation2008;27(8):856‐64. [MEDLINE: 18656798] ">Hollmen 2008</a>; <a href="./references#CD008927-bbs2-0055" title="VerledenG , FisherAJ , BoehlerA , EstenneM . Bronchiolitis obliterans syndrome. In: FisherAJ , VerledenG , MassardG editor(s). Lung transplantation. Plymouth, UK: European Respiratory Society Journals Ltd, 2009:197‐211. ">Verleden 2009</a>). Lung transplant recipients are also at high risk of developing morbidities that inhibit long‐term survival. Major morbidities in lung transplant recipients five years after transplantation are hypertension (85%), hyperlipidaemia (55%), diabetes mellitus (37%), and kidney dysfunction (36%) (<a href="./references#CD008927-bbs2-0025" title="ChristieJD , EdwardsLB , KucheryavayaAY , BendenC , DobbelsF , KirkR , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐eighth Adult Lung and Heart‐Lung Transplant Report‐‐2011. Journal of Heart &amp; Lung Transplantation2011;30(10):1104‐22. [MEDLINE: 21962018] ">Christie 2011</a>). </p> </section> <section id="CD008927-sec-0025"> <h3 class="title" id="CD008927-sec-0025">Description of the intervention</h3> <p>Immunological rejection of lungs means that transplant recipients are at risk of increased morbidity and reduced survival compared with the general population (<a href="./references#CD008927-bbs2-0025" title="ChristieJD , EdwardsLB , KucheryavayaAY , BendenC , DobbelsF , KirkR , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐eighth Adult Lung and Heart‐Lung Transplant Report‐‐2011. Journal of Heart &amp; Lung Transplantation2011;30(10):1104‐22. [MEDLINE: 21962018] ">Christie 2011</a>; <a href="./references#CD008927-bbs2-0040" title="LechlerRI , SykesM , ThomsonAW , TurkaLA . Organ transplantation‐‐how much of the promise has been realized?. Nature Medicine2005;11(6):605‐13. [MEDLINE: 15937473] ">Lechler 2005</a>; <a href="./references#CD008927-bbs2-0055" title="VerledenG , FisherAJ , BoehlerA , EstenneM . Bronchiolitis obliterans syndrome. In: FisherAJ , VerledenG , MassardG editor(s). Lung transplantation. Plymouth, UK: European Respiratory Society Journals Ltd, 2009:197‐211. ">Verleden 2009</a>). Finding the most effective immunosuppressive treatment strategy is essential to reduce morbidity and increase survival (<a href="./references#CD008927-bbs2-0037" title="IversenM , CorrisP . Immunosuppression. In: FisherAJ , VerledenG , MassardG editor(s). Lung transplantation. Plymouth, UK: European Respiratory Society Journals Ltd, 2009:147‐68. ">Iversen 2009</a>). </p> <p>Optimally, lung transplant recipients should develop immunological tolerance for grafts without compromising general immunity (<a href="./references#CD008927-bbs2-0024" title="ChenW , ZhangL . Regulatory T‐cell subsets and their roles in transplantation tolerance. Current Opinion in Organ Transplantation2006;11(4):373‐8. [EMBASE: 2006354779] ">Chen 2006</a>). Avoidance of adverse effects associated with immunosuppressive agents, such as kidney and cardiovascular diseases and malignancies enhance patients' survival (<a href="./references#CD008927-bbs2-0027" title="FlechnerSM , KobashigawaJ , KlintmalmG . Calcineurin inhibitor‐sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clinical Transplantation2008;22(1):1‐15. [MEDLINE: 18217899] ">Flechner 2008</a>; <a href="./references#CD008927-bbs2-0032" title="HauptmanPJ , MehraMR . It is time to stop ignoring malignancy in heart transplantation: a call to arms. Journal of Heart &amp; Lung Transplantation2005;24(8):1111‐3. [MEDLINE: 16102448] ">Hauptman 2005</a>). </p> <p>Maintenance immunosuppressive therapy for lung transplant recipients often involves three types of drugs directed against the T‐cell activation and proliferation cascade: antiproliferative agents (mycophenolate mofetil or azathioprine), calcineurin inhibitors (tacrolimus or cyclosporin), and steroids (prednisolone) (<a href="./references#CD008927-bbs2-0037" title="IversenM , CorrisP . Immunosuppression. In: FisherAJ , VerledenG , MassardG editor(s). Lung transplantation. Plymouth, UK: European Respiratory Society Journals Ltd, 2009:147‐68. ">Iversen 2009</a>). Mammalian target of rapamycin inhibitors (sirolimus or everolimus) may also be used as maintenance immunosuppression (<a href="./references#CD008927-bbs2-0037" title="IversenM , CorrisP . Immunosuppression. In: FisherAJ , VerledenG , MassardG editor(s). Lung transplantation. Plymouth, UK: European Respiratory Society Journals Ltd, 2009:147‐68. ">Iversen 2009</a>). The optimal combination and dose of these drugs has been the focus of much debate, especially given that calcineurin inhibitors are highly nephrotoxic, and the prolonged use of steroids causes several complications (<a href="./references#CD008927-bbs2-0027" title="FlechnerSM , KobashigawaJ , KlintmalmG . Calcineurin inhibitor‐sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clinical Transplantation2008;22(1):1‐15. [MEDLINE: 18217899] ">Flechner 2008</a>; <a href="./references#CD008927-bbs2-0037" title="IversenM , CorrisP . Immunosuppression. In: FisherAJ , VerledenG , MassardG editor(s). Lung transplantation. Plymouth, UK: European Respiratory Society Journals Ltd, 2009:147‐68. ">Iversen 2009</a>). No combination of these maintenance immunosuppressive agents has been completely successful in preventing acute and chronic rejection and graft failure without causing adverse reactions (<a href="./references#CD008927-bbs2-0037" title="IversenM , CorrisP . Immunosuppression. In: FisherAJ , VerledenG , MassardG editor(s). Lung transplantation. Plymouth, UK: European Respiratory Society Journals Ltd, 2009:147‐68. ">Iversen 2009</a>). </p> <p>Antibodies specific for T‐cells ‐ induction therapy ‐ have also been used to prevent rejection (<a href="./references#CD008927-bbs2-0030" title="HachemRR . Induction immunosuppression after lung transplantation. Current Opinion in Organ Transplantation2006;11(6):617‐20. [EMBASE: 2006573225] ">Hachem 2006</a>). The aim of T‐cell specific antibody induction therapy is to deplete circulating T‐cells immediately after transplantation before the full effect of calcineurin inhibitor treatment is achieved, thus diminishing rates of acute rejection following transplantation (<a href="./references#CD008927-bbs2-0037" title="IversenM , CorrisP . Immunosuppression. In: FisherAJ , VerledenG , MassardG editor(s). Lung transplantation. Plymouth, UK: European Respiratory Society Journals Ltd, 2009:147‐68. ">Iversen 2009</a>). It has also been suggested that temporary immune system manipulation using antibody induction against T‐cells to enhance graft acceptance may pave the way for long‐term reduction of maintenance immunosuppressive treatment (<a href="./references#CD008927-bbs2-0023" title="ChatenoudL . The long and winding road towards induction of allograft tolerance in the clinic. Transplant International2008;21(8):725‐7. [MEDLINE: 18573139] ">Chatenoud 2008</a>). </p> <p>Induction is usually commenced before or at the time of maintenance immunosuppressive therapy, and is typically used for a short period of time to avoid risks of severe infection and sepsis. Induction therapy enables delayed introduction or dose reduction of calcineurin inhibitors (<a href="./references#CD008927-bbs2-0037" title="IversenM , CorrisP . Immunosuppression. In: FisherAJ , VerledenG , MassardG editor(s). Lung transplantation. Plymouth, UK: European Respiratory Society Journals Ltd, 2009:147‐68. ">Iversen 2009</a>; <a href="./references#CD008927-bbs2-0047" title="RosenbergPB , VriesendorpAE , DraznerMH , DriesDL , KaiserPA , HynanLS , et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. Journal of Heart &amp; Lung Transplantation2005;24(9):1327‐31. [MEDLINE: 16143252] ">Rosenberg 2005</a>). </p> <p>Several T‐cell specific antibodies have been used. These include polyclonal antibodies of horse or rabbit (antithymocyte globulin (ATG) or antilymphocyte globulin (ALG)), or one of the monoclonal agents specific for the CD3 receptor (muromonab‐CD3), the CD52 surface protein (alemtuzumab), or interleukin‐2 receptor antagonists (IL‐2RA; daclizumab or basiliximab) (<a href="./references#CD008927-bbs2-0030" title="HachemRR . Induction immunosuppression after lung transplantation. Current Opinion in Organ Transplantation2006;11(6):617‐20. [EMBASE: 2006573225] ">Hachem 2006</a>; <a href="./references#CD008927-bbs2-0031" title="HachemRR , EdwardsLB , YusenRD , ChakinalaMM , Alexander PattersonG , TrulockEP . The impact of induction on survival after lung transplantation: an analysis of the International Society for Heart and Lung Transplantation Registry. Clinical Transplantation2008;22(5):603‐8. [MEDLINE: 18435784] ">Hachem 2008</a>; <a href="./references#CD008927-bbs2-0037" title="IversenM , CorrisP . Immunosuppression. In: FisherAJ , VerledenG , MassardG editor(s). Lung transplantation. Plymouth, UK: European Respiratory Society Journals Ltd, 2009:147‐68. ">Iversen 2009</a>). </p> <p>ATG, ALG, muromonab‐CD3, and alemtuzumab tend to eradicate functional T‐cell population from the circulation causing profound immunosuppression. The monoclonal IL‐2RA have been developed to increase immunosuppression specificity, with the aim of potentially avoiding over‐immunosuppression toxicity. The IL‐2RA exerts their effects through binding to the alpha subunit of the interleukin‐2 receptor found only on activated T‐cells. Interleukin‐2 receptor blockade prevents interleukin‐2 receptor‐stimulated clonal expression of the T‐cell (<a href="./references#CD008927-bbs2-0037" title="IversenM , CorrisP . Immunosuppression. In: FisherAJ , VerledenG , MassardG editor(s). Lung transplantation. Plymouth, UK: European Respiratory Society Journals Ltd, 2009:147‐68. ">Iversen 2009</a>). </p> </section> <section id="CD008927-sec-0026"> <h3 class="title" id="CD008927-sec-0026">Why it is important to do this review</h3> <p>The International Society for Heart and Lung Transplantation has reported that 50% of all transplant centres use T‐cell antibody induction for lung transplant recipients (<a href="./references#CD008927-bbs2-0025" title="ChristieJD , EdwardsLB , KucheryavayaAY , BendenC , DobbelsF , KirkR , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐eighth Adult Lung and Heart‐Lung Transplant Report‐‐2011. Journal of Heart &amp; Lung Transplantation2011;30(10):1104‐22. [MEDLINE: 21962018] ">Christie 2011</a>; <a href="./references#CD008927-bbs2-0037" title="IversenM , CorrisP . Immunosuppression. In: FisherAJ , VerledenG , MassardG editor(s). Lung transplantation. Plymouth, UK: European Respiratory Society Journals Ltd, 2009:147‐68. ">Iversen 2009</a>). Consensus on use of immunosuppressive antibody induction after lung transplantation has not yet been achieved (<a href="./references#CD008927-bbs2-0030" title="HachemRR . Induction immunosuppression after lung transplantation. Current Opinion in Organ Transplantation2006;11(6):617‐20. [EMBASE: 2006573225] ">Hachem 2006</a>; <a href="./references#CD008927-bbs2-0037" title="IversenM , CorrisP . Immunosuppression. In: FisherAJ , VerledenG , MassardG editor(s). Lung transplantation. Plymouth, UK: European Respiratory Society Journals Ltd, 2009:147‐68. ">Iversen 2009</a>). To enhance survival, it is essential to establish clear evidence to identify an optimal, safe and effective immunosuppressive treatment strategy for lung transplant recipients. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008927-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008927-sec-0027"></div> <p>We aimed to assess the benefits and harms of immunosuppressive T‐cell antibody induction with ATG, ALG, IL‐2RA, alemtuzumab, or muromonab‐CD3 for lung transplant recipients. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008927-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008927-sec-0028"></div> <section id="CD008927-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008927-sec-0030"> <h4 class="title">Types of studies</h4> <p>All randomised controlled trials (RCTs) assessing immunosuppressive induction with monoclonal or polyclonal antibodies against T‐cells for lung transplant recipients were sought. Quasi‐randomised and non‐randomised controlled studies that were identified were considered only for reporting of harms. </p> </section> <section id="CD008927-sec-0031"> <h4 class="title">Types of participants</h4> <p>We included all patients who had received their first isolated single or double lung transplantation. Data for adult and paediatric patients were planned to be analysed and reported separately because immunological differences in paediatric patients were expected (<a href="./references#CD008927-bbs2-0021" title="AuroraP , EdwardsLB , ChristieJD , DobbelsF , KirkR , RahmelAO , et al. Registry of the international society for heart and lung transplantation: twelfth official pediatric lung and heart/lung transplantation report‐2009. Journal of Heart &amp; Lung Transplantation2009;28(10):1023‐30. [MEDLINE: 19782284] ">Aurora 2009</a>). </p> </section> <section id="CD008927-sec-0032"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD008927-list-0001"> <li> <p>Studies comparing any dose and duration of immunosuppressive antibody induction with ATG, ALG, alemtuzumab, muromonab‐CD3, or IL‐2RA versus placebo or no intervention. </p> </li> <li> <p>One class of immunosuppressive T‐cell antibody induction versus another class of immunosuppressive T‐cell antibody induction (e.g. IL‐2RA versus ATG). </p> </li> <li> <p>Immunosuppressive T‐cell antibody preparation versus different formulation of same class antibody preparation (e.g. basiliximab versus daclizumab). </p> </li> </ol> </p> </section> <section id="CD008927-sec-0033"> <h4 class="title">Types of outcome measures</h4> <section id="CD008927-sec-0034"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD008927-list-0002"> <li> <p>Mortality</p> </li> <li> <p>Acute rejection (≥ A2) according to the classification of the International Society for Heart and Lung Transplantation (A0 (no rejection), A1 (minimal rejection), A2 (mild rejection), A3 (severe rejection); <a href="./references#CD008927-bbs2-0050" title="StewartS , FishbeinMC , SnellGI , BerryGJ , BoehlerA , BurkeMM , et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. Journal of Heart &amp; Lung Transplantation2007;26(12):1229‐42. [MEDLINE: 18096473] ">Stewart 2007</a>). We did not plan to evaluate secondary types of rejection such as airway inflammation related to bronchioles </p> </li> <li> <p>Adverse events. Serious adverse events were defined as any untoward medical occurrence that was life threatening, resulted in death, or persistent or significant disability, or any medical event which might have jeopardised the patient or required intervention/s to prevent it. All other adverse events (any medical occurrence not necessarily having a causal relationship with treatment) were considered as non‐serious (<a href="./references#CD008927-bbs2-0036" title="ICHGCP . International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Guideline for Good Clinical Practice. E6 (R1). http://ichgcp.net (accessed 1 October 2013). ">ICH GCP 1996</a>). </p> </li> </ol> </p> </section> <section id="CD008927-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD008927-list-0003"> <li> <p>Quality of life</p> </li> <li> <p>Infection</p> </li> <li> <p>Bronchiolitis obliterans syndrome</p> </li> <li> <p>Post‐transplantation lymphoproliferative disease (PTLD)</p> </li> <li> <p>Cancer</p> </li> <li> <p>Kidney injury requiring haemodialysis.</p> </li> </ol> </p> </section> </section> </section> <section id="CD008927-sec-0036"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008927-sec-0037"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Renal Group's specialised register to 4 March 2013 through contact with the Trials' Search Co‐ordinator using search terms relevant to this review. </p> <p>The Cochrane Renal Group’s specialised register contains studies identified from:</p> <p> <ol id="CD008927-list-0004"> <li> <p>Quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</p> </li> <li> <p>Weekly searches of MEDLINE OVID SP</p> </li> <li> <p>Handsearching of renal‐related journals and the proceedings of major renal conferences</p> </li> <li> <p>Searching of the current year of EMBASE OVID SP</p> </li> <li> <p>Weekly current awareness alerts for selected renal journals</p> </li> <li> <p>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</p> </li> </ol> </p> <p>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of the Cochrane Renal Group. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about the <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html" target="_blank">Cochrane Renal Group</a>. </p> <p>See <a href="./appendices#CD008927-sec-0137">Appendix 1</a> for search terms used in strategies for this review. </p> </section> <section id="CD008927-sec-0038"> <h4 class="title">Searching other resources</h4> <p> <ol id="CD008927-list-0005"> <li> <p>Reference lists of pulmonology and transplant textbooks, review articles, and relevant studies </p> </li> <li> <p>Letters seeking information about unpublished or incomplete studies to investigators known to be involved in previous studies </p> </li> <li> <p>Bibliographies of relevant articles</p> </li> <li> <p>US Food and Drug Administration (FDA) and European Medicines Agency (EMA) drug approval reviews </p> </li> <li> <p>The Science Citation Index Expanded (1945 to August 2011) (<a href="./references#CD008927-bbs2-0048" title="RoyleP , WaughN . Literature searching for clinical and cost‐effectiveness studies used in health technology assessment reports carried out for the National Institute for Clinical Excellence appraisal system. Health Technology Assessment (Winchester, England)2003;7(34):iii, ix‐x, 1‐51. [MEDLINE: 14609481] ">Royle 2003</a>). </p> </li> </ol> </p> </section> </section> <section id="CD008927-sec-0039"> <h3 class="title" id="CD008927-sec-0039">Data collection and analysis</h3> <section id="CD008927-sec-0040"> <h4 class="title">Selection of studies</h4> <p>The search strategy described was used to obtain titles and abstracts of studies that could be relevant to the review. Three authors independently assessed study eligibility. Excluded studies were listed with the reason for exclusion. Disagreements were resolved by discussion or in consultation with a third author. Study authors were contacted if information about methodology or data was unclear or missing. </p> </section> <section id="CD008927-sec-0041"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was carried out independently by two authors using standard data extraction forms (<a href="./references#CD008927-bbs2-0034" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>; <a href="./references#CD008927-bbs2-0043" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006‐12. [MEDLINE: 19631508] ">Moher 2009</a>). Studies reported in non‐English language journals were planned to be translated before assessment. Where more than one publication of one study existed, publications were grouped together and the publication with the most complete data were used. Where relevant outcomes were only published in earlier versions we planned to use these data. Any discrepancy between published versions was planned to be highlighted. Any further information required from the original author was requested by written correspondence and any relevant information obtained in this manner was included in the review. Disagreements were resolved by consultation among all authors. </p> <p>We extracted the following information from each study: first author, country of origin, study design, inclusion and exclusion criteria, number of participants, patient characteristics, study drugs, dose, administration, additional immunosuppression, follow‐up period, primary and secondary outcomes, adverse events, and patients lost to follow‐up. </p> </section> <section id="CD008927-sec-0042"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The following items were independently assessed by two authors using the risk of bias assessment tool (<a href="./references#CD008927-bbs2-0034" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) (see <a href="./appendices#CD008927-sec-0138">Appendix 2</a>). </p> <p> <ul id="CD008927-list-0006"> <li> <p>Was there adequate sequence generation (selection bias)?</p> </li> <li> <p>Was allocation adequately concealed (selection bias)?</p> </li> <li> <p>Was knowledge of the allocated interventions adequately prevented during the study (detection bias)? </p> <ul id="CD008927-list-0007"> <li> <p>Participants and personnel</p> </li> <li> <p>Outcome assessors</p> </li> </ul> </li> <li> <p>Were incomplete outcome data adequately addressed (attrition bias)?</p> </li> <li> <p>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)? </p> </li> <li> <p>Was the study apparently free of other problems that could put it at a risk of bias?</p> </li> </ul> </p> <p>Studies assessed as adequately reporting generation of the allocation sequence, allocation concealment, blinding, outcome data reporting, with no evidence of selective outcome reporting, and without vested interests were considered to be at low risk of bias (<a href="./references#CD008927-bbs2-0028" title="GluudLL . Bias in clinical intervention research. American Journal of Epidemiology2006;163(6):493‐501. [MEDLINE: 16443796] ">Gluud 2006</a>; <a href="./references#CD008927-bbs2-0039" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. [MEDLINE: 11730399] ">Kjaergard 2001</a>; <a href="./references#CD008927-bbs2-0042" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. [MEDLINE: 9746022] ">Moher 1998</a>; <a href="./references#CD008927-bbs2-0049" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. [MEDLINE: 7823387] ">Schulz 1995</a>; <a href="./references#CD008927-bbs2-0059" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. [MEDLINE: 18316340] ">Wood 2008</a>). Studies assessed to include one or more unclear or inadequate quality components were considered to be at high risk of bias (<a href="./references#CD008927-bbs2-0042" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. [MEDLINE: 9746022] ">Moher 1998</a>; <a href="./references#CD008927-bbs2-0049" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. [MEDLINE: 7823387] ">Schulz 1995</a>; <a href="./references#CD008927-bbs2-0059" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. [MEDLINE: 18316340] ">Wood 2008</a>). High inter‐rater agreement between blinded and unblinded assessments as well as between independent assessors has been found previously (<a href="./references#CD008927-bbs2-0028" title="GluudLL . Bias in clinical intervention research. American Journal of Epidemiology2006;163(6):493‐501. [MEDLINE: 16443796] ">Gluud 2006</a>; <a href="./references#CD008927-bbs2-0039" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. [MEDLINE: 11730399] ">Kjaergard 2001</a>). </p> </section> <section id="CD008927-sec-0043"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes results were expressed as risk ratio (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment, the mean difference (MD) were used, or the standardised mean difference (SMD) if different scales had been used (<a href="./references#CD008927-bbs2-0033" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>; <a href="./references#CD008927-bbs2-0052" title="ThompsonSG , HigginsJP . How should meta‐regression analyses be undertaken and interpreted?. Statistics in Medicine2002;21(11):1559‐73. [MEDLINE: 12111920] ">Thompson 2002</a>). </p> </section> <section id="CD008927-sec-0044"> <h4 class="title">Dealing with missing data</h4> <p> <ul id="CD008927-list-0008"> <li> <p>Contacted original investigators to request missing data.</p> </li> <li> <p>Performed sensitivity analyses to assess how sensitive results were to reasonable changes in the assumptions that are made. We performed worst‐worst case scenario analyses, best‐best case scenario analyses, worst‐best case scenario analyses, and best‐worst case scenario analyses. </p> </li> </ul> </p> </section> <section id="CD008927-sec-0045"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was analysed using a Chi² test on N‐1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I² test (<a href="./references#CD008927-bbs2-0033" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity. </p> </section> <section id="CD008927-sec-0046"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to construct funnel plots to explore bias if more than 10 studies were included in this review (<a href="./references#CD008927-bbs2-0026" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. [MEDLINE: 9310563] ">Egger 1997</a>; <a href="./references#CD008927-bbs2-0041" title="MacaskillP , WalterSD , IrwigL . A comparison of methods to detect publication bias in meta‐analysis. Statistics in Medicine2001;20(4):641‐54. [MEDLINE: 11223905] ">Macaskill 2001</a>). However, the small number of included studies (6) meant that this could not be undertaken. </p> </section> <section id="CD008927-sec-0047"> <h4 class="title">Data synthesis</h4> <p>Data were pooled using the random‐effects model and the fixed‐effect model was used to ensure data robustness. </p> </section> <section id="CD008927-sec-0048"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>The following subgroup analyses were planned to be undertaken.</p> <p> <ol id="CD008927-list-0009"> <li> <p>Individual antibody preparation compared with other classes of antibody preparation (e.g. ATG versus IL‐2RA) </p> </li> <li> <p>Antibody preparation compared to different formulation of same class antibody preparation (e.g. basiliximab versus daclizumab) </p> </li> <li> <p>Comparisons of studies at low risk of bias with studies at high risk of bias</p> </li> <li> <p>Studies with early initiation of calcineurin inhibitor (at the time of transplantation) compared to studies with late initiation of calcineurin inhibitor (one to two weeks after transplantation). </p> </li> </ol> </p> </section> <section id="CD008927-sec-0049"> <h4 class="title">Sensitivity analysis</h4> <section id="CD008927-sec-0050"> <h5 class="title">Zero‐event trials</h5> <p>The principal analysis tool used for this review, Review Manager 5, was not designed to analyse studies with zero events when meta‐analyses are performed as relative risk or odds ratios. It seemed unjustified and unreasonable to exclude zero event studies (<a href="./references#CD008927-bbs2-0038" title="KeusF , WetterslevJ , GluudC , GooszenHG , vanLaarhovenCJ . Robustness assessments are needed to reduce bias in meta‐analyses that include zero‐event randomized trials. American Journal of Gastroenterology2009;104(3):546‐51. [MEDLINE: 19262513] ">Keus 2009</a>) that would potentially create a risk of inflating the magnitude of the pooled treatment effects. We therefore performed a random‐effects meta‐analysis with empirical continuity correction of 0.01 in studies with zero events (<a href="./references#CD008927-bbs2-0051" title="SweetingMJ , SuttonAJ , LambertPC . What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data. Statistics in Medicine2004;23(9):1351‐75. [MEDLINE: 15116347] ">Sweeting 2004</a>). </p> </section> <section id="CD008927-sec-0051"> <h5 class="title">Trial sequential analysis</h5> <p>Trial sequential analysis was conducted because cumulative meta‐analyses carry risks of producing random errors due to sparse data and repetitive testing on accumulating data (<a href="./references#CD008927-bbs2-0053" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis‐‐a simulation study. PLoS One [Electronic Resource]2011;6(10):e25491. [MEDLINE: 22028777] ">Thorlund 2011</a>; <a href="./references#CD008927-bbs2-0054" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark, 2011. http://www.ctu.dk/tsa/files/tsa_manual.pdf (accessed 1 October 2013). ">TSA 2011</a>; <a href="./references#CD008927-bbs2-0057" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>). We calculated the required information size, that is, the number of participants needed in a meta‐analysis to detect or reject a certain intervention effect, to minimise random errors (<a href="./references#CD008927-bbs2-0057" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>; <a href="./references#CD008927-bbs2-0058" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology2009;9:86. [MEDLINE: 20042080] ">Wetterslev 2009</a>). Information size calculation should also account for heterogeneity in the meta‐analysis. </p> <p>In our meta‐analyses, information size was based on an assumed plausible relative risk reduction of 20% or on the relative risk reduction observed in the included studies assessed as low risk of bias (<a href="./references#CD008927-bbs2-0057" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>). </p> <p>The underlying assumption of trial sequential analysis is that significance testing may be performed each time a new study is added to the meta‐analysis. We planned to add studies according to publication year, and if more than one study was published in a year, to add these in alphabetical order according to the family name of the first author. </p> <p>The required information size was calculated and the trial sequential alpha‐spending and beta‐spending monitoring boundaries were constructed on the basis of the risk for type I (5%) and type II (20%) errors, nominated relative risk, proportion with the outcome in the control group, and observed heterogeneity (<a href="./references#CD008927-bbs2-0054" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark, 2011. http://www.ctu.dk/tsa/files/tsa_manual.pdf (accessed 1 October 2013). ">TSA 2011</a>; <a href="./references#CD008927-bbs2-0057" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>). These boundaries determined the statistical inference that may be drawn regarding cumulative meta‐analyses not achieving the required information size. If a trial sequential monitoring boundary is crossed before the required information size is reached in a cumulative meta‐analysis, firm evidence may have been established and further studies may be superfluous. Conversely, if the alpha‐ and beta‐spending boundaries are not surpassed, it is probably necessary to continue adding studies to detect or reject a certain intervention effect. Defaults used were: type I error, 5%; type II error, 20%; and adjusted information size for diversity unless otherwise stated (<a href="./references#CD008927-bbs2-0053" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta‐analysis‐‐a simulation study. PLoS One [Electronic Resource]2011;6(10):e25491. [MEDLINE: 22028777] ">Thorlund 2011</a>; <a href="./references#CD008927-bbs2-0057" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008927-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008927-sec-0052"></div> <section id="CD008927-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD008927-sec-0054"> <h4 class="title">Results of the search</h4> <p>The search strategy described identified 134 references, and we found another 12 references from other sources. After exclusions, six studies (nine publications; six peer‐reviewed journal articles, two conference abstracts, and one study from ClinicalTrials.gov) were included in our review. <a href="#CD008927-fig-0001">Figure 1</a> depicts the results of our search strategy. </p> <div class="figure" id="CD008927-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD008927-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD008927-sec-0055"> <h4 class="title">Included studies</h4> <p>We included six single‐centre studies that enrolled 278 participants (<a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a>; <a href="./references#CD008927-bbs2-0002" title="ChaparroC , GutierrezCA , KestenS , HutcheonM , WintonT , SnellG , et al. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):46. ">Chaparro 1999</a>; <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>; <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a>; <a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a>; <a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a>). </p> <p><a href="./references#CD008927-bbs2-0002" title="ChaparroC , GutierrezCA , KestenS , HutcheonM , WintonT , SnellG , et al. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):46. ">Chaparro 1999</a> (60 participants) compared ALG versus placebo; <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a> (44 participants) compared ATG versus no intervention; <a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a> (64 participants) compared ATG versus muromonab‐CD3; <a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a> (50 participants) compared ATG versus daclizumab; <a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a> (24 participants) compared ATG versus basiliximab; and <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> (36 participants) randomised participants to three groups: ATG, daclizumab, or no intervention. </p> <p>We compared T‐cell antibody induction versus no T‐cell antibody induction (3 studies, 140 participants; <a href="./references#CD008927-bbs2-0002" title="ChaparroC , GutierrezCA , KestenS , HutcheonM , WintonT , SnellG , et al. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):46. ">Chaparro 1999</a>; <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>; <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a>); polyclonal T‐cell antibody induction versus no T‐cell antibody induction (3 studies, 125 participants; <a href="./references#CD008927-bbs2-0002" title="ChaparroC , GutierrezCA , KestenS , HutcheonM , WintonT , SnellG , et al. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):46. ">Chaparro 1999</a>; <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>; <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a>); polyclonal T‐cell antibody induction versus muromonab‐CD3 induction (1 study, 64 participants; <a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a>); polyclonal T‐cell antibody induction versus IL‐2RA induction (3 studies, 100 participants; <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>; <a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a>; <a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a>); and IL‐2RA induction versus no T‐cell antibody induction (1 study, 25 participants; <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>). </p> <p>Participants in all included studies were adults. Mean age of the total study population was reported in four studies (range: 49 to 53 years) (<a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a>; <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>; <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a>; <a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a>). With one possible exception, mean ages of participants in single‐centre study treatment groups were similar (<a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a>; <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a>; <a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a>). In <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>, the mean ages of participants were 49 years in the daclizumab treatment arm; and 58 years and 53 years in the ATG and control groups respectively. </p> <p>Five studies reported on numbers of single versus double lung transplant recipients (<a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a>; <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>; <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a>; <a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a>; <a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a>). In three studies, more than half were single lung transplantations (<a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a>; <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>; <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a>). <a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a> reported that more than 70% were double lung transplantations; all participants in <a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a> were double lung transplant recipients (100%). Numbers of single and double lung transplantations were similar among treatment groups in the single‐centre studies. </p> <p><a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a> and <a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a> examined ATG derived from horse (ATGAM®), <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> and <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a> investigated rabbit ATG (Thymoglobulin®); the type of ATG was unclear in <a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a>. </p> <p>Although maintenance immunosuppressive treatments were the same in all studies, immunosuppressive treatments varied. A triple immunosuppression regimen was used in five studies (<a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a>; <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>; <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a>; <a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a>; <a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a>); <a href="./references#CD008927-bbs2-0002" title="ChaparroC , GutierrezCA , KestenS , HutcheonM , WintonT , SnellG , et al. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):46. ">Chaparro 1999</a> did not report maintenance immunosuppression. Participants in all studies received steroid therapy and calcineurin inhibitors; in four studies, the calcineurin inhibitor was cyclosporin (<a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a>; <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>; <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a>; <a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a>); <a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a> administered either tacrolimus or cyclosporin. <a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a> and <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a> administered azathioprine as an antiproliferative agent; and mycophenolate mofetil was used in <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>, <a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a> and <a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a>. </p> <p>Follow‐up varied from six months (<a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a>), 12 months (<a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a>), 2 years (<a href="./references#CD008927-bbs2-0002" title="ChaparroC , GutierrezCA , KestenS , HutcheonM , WintonT , SnellG , et al. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):46. ">Chaparro 1999</a>; <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>; <a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a>) and 8 years (<a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a>). </p> <p>All included studies were published in English.</p> </section> <section id="CD008927-sec-0056"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD008927-sec-0147" title="">Characteristics of excluded studies</a>. </p> <p>We excluded 10 studies after full‐text assessment (<a href="./references#CD008927-bbs2-0007" title="BhoradeSM , AhyaV , KotloffR , BazM , ValentineV , ArcasoyS , et al. Long term follow‐up in the AIRSAC Trial, a multicenter randomized clinical trial in lung transplant recipients [abstract]. Journal of Heart &amp; Lung Transplantation2009;28(2 Suppl 1):S119‐20. [EMBASE: 70140164] ShyuS , DewMA , DeVito DabbsA , CrespoM , ZaldonisDB , JohnsonBA , et al. Long term follow‐up in the AIRSAC Trial, a multicenter randomized clinical trial in lung transplant recipients [abstract]. Journal of Heart &amp; Lung Transplantation2009;28(2 Suppl 1):S68. ">AIRSAC Trial 2009</a>; <a href="./references#CD008927-bbs2-0008" title="BarlowCW , MoonMR , GreenGR , GambergP , TheodoreJ , ReitzBA , et al. Rabbit antithymocyte globulin versus OKT3 induction therapy after heart‐lung and lung transplantation: Effect on survival, rejection, infection, and obliterative bronchiolitis. Transplant International2001;14(4):234‐9. [MEDLINE: 11512056] ">Barlow 2001</a>; <a href="./references#CD008927-bbs2-0009" title="BorroJM , De laTorreM , MiguelezC , FernandezR , GonzalezD , LemosC . Comparative study of basiliximab treatment in lung transplantation. Transplantation Proceedings2005;37(9):3996‐8. [MEDLINE: 16386608] ">Borro 2005</a>; <a href="./references#CD008927-bbs2-0011" title="GeldmacherH , HoperM , BlachM , StruberM , WirsingM , HaverichA , et al. The effect of total nodal irradiation and ATG therapy in the treatment of obliterative bronchiolitis after lung transplantation [abstract]. Pneumologie2001;55(SH1):S64. ">Geldmacher 2001</a>; <a href="./references#CD008927-bbs2-0012" title="JakschP , NierlichP , ScheedA , ErnstMB , AugustinV , AignerC , et al. Alemtuzumab induction in lung transplantation: efficacy and safety [abstract]. European Surgery ‐ Acta Chirurgica Austriaca2011;43(Suppl 242):27. [EMBASE: 70582326] JakschP , ScheedA , ZweytickB , ErnstM , AugustinV , KlepetkoW . Alemtuzumab induction in lung transplantation: efficacy and safety [abstract]. Journal of Heart &amp; Lung Transplantation2012;31(4 Suppl 1):S67. [EMBASE: 70734276] ">Jaksch 2011</a>; <a href="./references#CD008927-bbs2-0013" title="LawrenceEC , HollandVA , YoungJB , WindsorNT , BrousseauKP , NoonGP , et al. Dynamic changes in soluble interleukin‐2 receptor levels after lung or heart‐lung transplantation. American Review of Respiratory Disease1989;140(3):789‐96. [MEDLINE: 2506785] ">Lawrence 1989</a>; <a href="./references#CD008927-bbs2-0014" title="LischkeR , SimonekJ , Davidova R , SchutznerJ , StolzAJ , VojácekJ , et al. Induction therapy in lung transplantation: initial single‐center experience comparing daclizumab and antithymocyte globulin. Transplantation Proceedings2007;39(1):205‐12. [MEDLINE: 17275507] ">Lischke 2007</a>; <a href="./references#CD008927-bbs2-0015" title="MaromEM , ChoiYW , PalmerSM , DeLongDM , StuartMD , McAdamsHP . Reperfusion edema after lung transplantation: effect of daclizumab. Radiology2001;221(2):508‐14. [MEDLINE: 11687697] ">Marom 2001</a>; <a href="./references#CD008927-bbs2-0016" title="MeiserBM , UberfuhrP , SchulzeC , FuchsA , MairH , ReichenspurnerH , et al. Tacrolimus (FK506) proves superior to OKT3 for treating episodes of persistent rejection following intrathoracic transplantation. Transplantation Proceedings1997;29(1‐2):605‐6. [MEDLINE: 9123150] ">Meiser 1997</a>; <a href="./references#CD008927-bbs2-0017" title="vanLoenhoutKC , GrovesSC , GalazkaM , ShermanB , BrittE , GarciaJ , et al. Early outcomes using alemtuzumab induction in lung transplantation. Interactive Cardiovascular &amp; Thoracic Surgery2010;10(2):190‐4. [MEDLINE: 19939852] ">van Loenhout 2010</a>). None of these studies assessed T‐cell antibody induction in randomised settings with the use of concomitant immunosuppression. </p> </section> </section> <section id="CD008927-sec-0057"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, study methodology was inadequately reported (<a href="#CD008927-fig-0002">Figure 2</a>; <a href="#CD008927-fig-0003">Figure 3</a>) and all included studies were assessed to be at high risk of bias (<a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a>; <a href="./references#CD008927-bbs2-0002" title="ChaparroC , GutierrezCA , KestenS , HutcheonM , WintonT , SnellG , et al. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):46. ">Chaparro 1999</a>; <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>; <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a>; <a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a>; <a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a>). </p> <div class="figure" id="CD008927-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD008927-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD008927-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD008927-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD008927-sec-0058"> <h4 class="title">Allocation</h4> <p>Sequence generation allocation using computer‐generated randomisation was reported adequately by <a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a>; was unclear in <a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a>, and was not reported in <a href="./references#CD008927-bbs2-0002" title="ChaparroC , GutierrezCA , KestenS , HutcheonM , WintonT , SnellG , et al. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):46. ">Chaparro 1999</a>, <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>, <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a> or <a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a>. </p> <p>Allocation concealment was not reported in any of the included studies.</p> </section> <section id="CD008927-sec-0059"> <h4 class="title">Blinding</h4> <p>Despite reporting that randomisation was double‐blinded, <a href="./references#CD008927-bbs2-0002" title="ChaparroC , GutierrezCA , KestenS , HutcheonM , WintonT , SnellG , et al. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):46. ">Chaparro 1999</a> provided no further information. Neither <a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a> nor <a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a> reported blinding; and <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> was not blinded. Two studies reported partial blinding: <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a> reported that pathologists who examined transbronchial lung biopsy specimens were blinded to the study drug assignment; participants and outcome assessors were not blinded. <a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a> reported that although study participants were blinded, personnel and outcome assessors were not. </p> </section> <section id="CD008927-sec-0060"> <h4 class="title">Incomplete outcome data</h4> <p>Outcome data reporting was incomplete in five studies (<a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a>; <a href="./references#CD008927-bbs2-0002" title="ChaparroC , GutierrezCA , KestenS , HutcheonM , WintonT , SnellG , et al. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):46. ">Chaparro 1999</a>; <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>; <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a>; <a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a>; <a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a>), but in four of these, omissions did not put them at risk of bias (<a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a>; <a href="./references#CD008927-bbs2-0002" title="ChaparroC , GutierrezCA , KestenS , HutcheonM , WintonT , SnellG , et al. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):46. ">Chaparro 1999</a>; <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a>; <a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a>). Five patients died within 30 days following transplantation (group allocations not clear), and were excluded from the analysis by <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>; hence, data analysis was per‐protocol. Incomplete data was not reported by <a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a>. </p> </section> <section id="CD008927-sec-0061"> <h4 class="title">Selective reporting</h4> <p>Although we had access to the <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> study protocol, we were unable to obtain protocols for the other included studies. However, all reported on expected clinical outcome measures (<a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a>; <a href="./references#CD008927-bbs2-0002" title="ChaparroC , GutierrezCA , KestenS , HutcheonM , WintonT , SnellG , et al. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):46. ">Chaparro 1999</a>; <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a>; <a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a>; <a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a>). </p> </section> <section id="CD008927-sec-0062"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a> was industry‐sponsored. We identified no other issues that could be construed as imposing risk of bias in four studies (<a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a>; <a href="./references#CD008927-bbs2-0002" title="ChaparroC , GutierrezCA , KestenS , HutcheonM , WintonT , SnellG , et al. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):46. ">Chaparro 1999</a>; <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>; <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a>). <a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a> did not appear to have any other potential sources of bias, however this was an abstract‐only report (with no additional data provided) and therefore we have assessed the bias as unclear. </p> </section> </section> <section id="CD008927-sec-0063"> <h3 class="title" id="CD008927-sec-0063">Effects of interventions</h3> <p>See: <a href="./full#CD008927-tbl-0001"><b>Summary of findings for the main comparison</b> T‐cell antibody induction compared with no antibody induction for lung transplant recipients</a>; <a href="./full#CD008927-tbl-0002"><b>Summary of findings 2</b> Polyclonal T‐cell antibody compared with no antibody induction for lung transplant recipients</a>; <a href="./full#CD008927-tbl-0003"><b>Summary of findings 3</b> IL‐2 receptor antagonist induction compared with no antibody induction for lung transplant recipients</a>; <a href="./full#CD008927-tbl-0004"><b>Summary of findings 4</b> Polyclonal T‐cell antibody induction compared with interleukin‐2 receptor antagonist induction for lung transplant recipients</a> </p> <section id="CD008927-sec-0064"> <h4 class="title">Polyclonal or monoclonal T‐cell antibody induction versus no induction</h4> <p><a href="./references#CD008927-bbs2-0002" title="ChaparroC , GutierrezCA , KestenS , HutcheonM , WintonT , SnellG , et al. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):46. ">Chaparro 1999</a> (60 participants) compared ALG versus placebo; <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a> (44 participants) compared ATG versus no intervention; <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> (36 participants) randomised patients to three groups: ATG, daclizumab, or no intervention. </p> <section id="CD008927-sec-0065"> <h5 class="title">Mortality</h5> <p>There was no significant difference in the number of deaths between patients treated with any kind of antibody induction compared with placebo or no induction (33/82 (40%) versus 26/58 (45%), (<a href="./references#CD008927-fig-0005" title="">Analysis 1.1</a> (3 studies, 140 participants): RR 0.93, 95% CI 0.67 to 1.27; I² = 0%). Analysis showed that trial sequential monitoring boundaries were not broken by the cumulative Z‐curve, and the required information size of 935 participants was not obtained (<a href="#CD008927-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD008927-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Any induction versus no induction; mortality: trial sequential analysis of the effect of induction versus no induction on mortality based on three studies (140 participants). The required information size of 935 patients was calculated based on type I error of 5%, type II error of 20%, risk reduction of 20%, and information size was adjusted for heterogeneity (I² = 0%)" data-id="CD008927-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Any induction versus no induction; mortality: trial sequential analysis of the effect of induction versus no induction on mortality based on three studies (140 participants). The required information size of 935 patients was calculated based on type I error of 5%, type II error of 20%, risk reduction of 20%, and information size was adjusted for heterogeneity (I² = 0%) </p> </div> </div> </div> </section> <section id="CD008927-sec-0066"> <h5 class="title">Acute rejection</h5> <p>Acute rejection was defined as the number of patients who experienced at least one episode of rejection. There was no significant difference in the number of patients experiencing acute rejection between those treated with any kind of antibody induction compared with placebo or no induction (29/82 (35%) versus 28/58 (48%) (<a href="./references#CD008927-fig-0006" title="">Analysis 1.2</a> (3 studies, 140 participants): RR 0.68, 95% CI 0.33 to 1.41; I² = 62%). Analysis showed that trial sequential monitoring boundaries were not broken by the cumulative Z‐curve, and the required information size of 2200 participants was not obtained. </p> </section> <section id="CD008927-sec-0067"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a> reported that no other adverse events occurred in any of the treatment groups (<a href="./references#CD008927-fig-0007" title="">Analysis 1.3</a>). <a href="./references#CD008927-bbs2-0002" title="ChaparroC , GutierrezCA , KestenS , HutcheonM , WintonT , SnellG , et al. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):46. ">Chaparro 1999</a> and <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> did not report adverse events. Therefore, only the zero event study (<a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a>) contributed data for analysis, and consequently, a meta‐analysis using zero event correction was not conducted. </p> </section> <section id="CD008927-sec-0068"> <h5 class="title">Quality of life</h5> <p>Quality of life measures were not reported.</p> </section> <section id="CD008927-sec-0069"> <h5 class="title">Infection</h5> <p>Infection was defined as the number of patients who experienced at least one episode of infection. There was no significant difference in the number of infections between those treated with any kind of antibody induction compared to placebo or no intervention (36/56 (64%) versus 22/48 (46%) (<a href="./references#CD008927-fig-0008" title="">Analysis 1.4</a> (2 studies, 104 participants): RR 1.40, 95% CI 0.97 to 2.01; I² = 0%). </p> <section id="CD008927-sec-0070"> <h6 class="title">Pneumonia (viral, bacterial, or fungal)</h6> <p>Pneumonia was defined as the number of patients who experienced at least one episode of pneumonia. There was no significant difference in the number of patients with pneumonia between those treated with any kind of antibody induction compared with placebo or no induction (33/60 (55%) versus 14/36 (39%), (<a href="./references#CD008927-fig-0009" title="">Analysis 1.5</a> (2 studies, 96 participants): RR 1.38, 95% CI 0.18 to 10.63; I² = 94%). </p> </section> <section id="CD008927-sec-0071"> <h6 class="title">Cytomegalovirus infection</h6> <p>There was no significant difference in the number of patients with cytomegalovirus infection between those treated with antibody induction compared with placebo or no induction (25/48 (52%) versus 15/32 (47%), (<a href="./references#CD008927-fig-0010" title="">Analysis 1.6</a> (2 studies 80 participants): RR 1.14, 95% CI 0.73 to 1.80; I² = 0%). </p> </section> </section> <section id="CD008927-sec-0072"> <h5 class="title">Bronchiolitis obliterans syndrome</h5> <p>There was no significant difference in the number of patients with bronchiolitis obliterans syndrome between those treated with antibody induction compared with placebo or no induction (30/82 (37%) versus 31/58 (53%), (<a href="./references#CD008927-fig-0011" title="">Analysis 1.7</a> (3 studies, 140 participants): RR 0.74, 95% CI 0.51 to 1.07; I² = 10%). </p> </section> <section id="CD008927-sec-0073"> <h5 class="title">Post‐transplantation lymphoproliferative disease</h5> <p><a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a> reported no significant difference in the number of patients diagnosed with PTLD between those treated with any kind of antibody induction compared with no induction (1/22 (5%) versus 0/22 (0%), (<a href="./references#CD008927-fig-0012" title="">Analysis 1.8</a> (1 study, 44 participants) RR 3.00, 95% CI 0.13 to 69.87). This was confirmed using Fisher's exact test (P = 1.0) </p> </section> <section id="CD008927-sec-0074"> <h5 class="title">Cancer</h5> <p><a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a> reported no significant difference in the number of patients diagnosed with cancer between the antibody induction group compared with the no induction group (8/22 (36%) versus 3/22 (14%), (<a href="./references#CD008927-fig-0013" title="">Analysis 1.9</a> (1 study, 44 participants): RR 2.67, 95% CI 0.81 to 8.75). This was confirmed using Fisher's exact test (P = 0.16). The eight malignancies reported in antibody induction group included three non‐small cell lung cancers, one prostate cancer, one squamous cell nasopharynx cancer, and four skin cancers. There were three malignancies reported among control group: one non‐small cell lung cancer and two skin cancers. </p> </section> <section id="CD008927-sec-0075"> <h5 class="title">Kidney injury requiring haemodialysis</h5> <p>Kidney injury requiring haemodialysis was not reported.</p> </section> </section> <section id="CD008927-sec-0076"> <h4 class="title">Polyclonal T‐cell antibody versus no induction</h4> <p><a href="./references#CD008927-bbs2-0002" title="ChaparroC , GutierrezCA , KestenS , HutcheonM , WintonT , SnellG , et al. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):46. ">Chaparro 1999</a> (60 participants) compared ALG versus placebo, and <a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a> (44 participants) compared ATG versus no intervention. <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> (36 participants) randomised patients to three groups: ATG, daclizumab or no intervention. The 15 patients who received daclizumab in <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> were excluded from the analyses. </p> <section id="CD008927-sec-0077"> <h5 class="title">Mortality</h5> <p>There was no significant difference in the number of deaths between patients treated with polyclonal antibody induction compared with no induction (29/67 (43%) versus 26/58 (45%), (<a href="./references#CD008927-fig-0014" title="">Analysis 2.1</a> (3 studies, 125 participants): RR 0.94, 95% CI 0.66 to 1.31; I² = 0%). Analysis showed that trial sequential monitoring boundaries were not broken by the cumulative Z‐curve, and the required information size of 935 patients was not achieved. </p> </section> <section id="CD008927-sec-0078"> <h5 class="title">Acute rejection</h5> <p>There was no significant difference in the number of patients experiencing acute rejection between those treated with polyclonal T‐cell antibody induction compared with no induction (21/67 (31%) versus 28/58 (48%), (<a href="./references#CD008927-fig-0015" title="">Analysis 2.2</a> (3 studies, 125 participants): RR 0.68, 95% CI 0.44 to 1.04; I² = 75%). Analysis showed that trial sequential monitoring boundaries were not broken by the cumulative Z‐curve, and the required information size of 3344 patients was not achieved. </p> </section> <section id="CD008927-sec-0079"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a> reported that no other adverse events occurred in any of the treatment groups (<a href="./references#CD008927-fig-0016" title="">Analysis 2.3</a>). <a href="./references#CD008927-bbs2-0002" title="ChaparroC , GutierrezCA , KestenS , HutcheonM , WintonT , SnellG , et al. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant [abstract]. Journal of Heart &amp; Lung Transplantation1999;18(1):46. ">Chaparro 1999</a> and <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> did not report adverse events. Therefore, only the zero event study (<a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a>) contributed data for analysis, and consequently, a meta‐analysis using zero event correction was not conducted. </p> </section> <section id="CD008927-sec-0080"> <h5 class="title">Quality of life</h5> <p>Quality of life measures were not reported.</p> </section> <section id="CD008927-sec-0081"> <h5 class="title">Infection</h5> <p>There was no significant difference in the number of infections between patients treated with polyclonal T‐cell antibody induction compared with no induction (36/56 (64%) versus 22/48 (46%), (<a href="./references#CD008927-fig-0017" title="">Analysis 2.4</a> (2 studies, 104 participants): RR 1.40, 95% CI 0.97 to 2.01; I² = 0%). </p> <section id="CD008927-sec-0082"> <h6 class="title">Pneumonia (viral, bacterial, and fungal)</h6> <p>There was no significant difference in the number of patients with pneumonia between those treated with polyclonal T‐cell antibody induction compared with no induction (23/45 (51%) versus 14/36 (39%), (<a href="./references#CD008927-fig-0018" title="">Analysis 2.5</a> (2 studies, 81 participants): RR 1.40, 95% CI 0.97 to 2.01; I² = 92%). </p> </section> <section id="CD008927-sec-0083"> <h6 class="title">Cytomegalovirus infection</h6> <p>There was no significant difference in the number of patients with cytomegalovirus infection between those treated with polyclonal T‐cell antibody induction compared with no induction (19/33 (58%) versus 15/32 (47%), (<a href="./references#CD008927-fig-0019" title="">Analysis 2.6</a> (2 studies, 65 participants): RR 1.23, 95% CI 0.77 to 1.97; I² = 0%). </p> </section> </section> <section id="CD008927-sec-0084"> <h5 class="title">Bronchiolitis obliterans syndrome</h5> <p>There was no significant difference in the number of patients with bronchiolitis obliterans syndrome between those treated with polyclonal T‐cell antibody induction compared with no induction (28/67 (42%) versus 31/58 (53%), (<a href="./references#CD008927-fig-0020" title="">Analysis 2.7</a> (3 studies, 125 participants): RR 0.76, 95% CI 0.56 to 1.05; I² = 0%). </p> </section> <section id="CD008927-sec-0085"> <h5 class="title">Post‐transplantation lymphoproliferative disease</h5> <p><a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a> reported no significant difference in the number of patients diagnosed with PTLD between those treated with polyclonal T‐cell antibody induction compared with no induction (1/22 (5%) versus 0/22 (0%), (<a href="./references#CD008927-fig-0021" title="">Analysis 2.8</a> (1 study, 44 participants): RR 3.00, 95% CI 0.13 to 69.87). This was confirmed using Fisher's exact test (P = 1.0). </p> </section> <section id="CD008927-sec-0086"> <h5 class="title">Cancer</h5> <p><a href="./references#CD008927-bbs2-0004" title="HartwigMG , SnyderLD , AppelJZ3rd , CantuE3rd , LinSS , PalmerSM , et al. Rabbit anti‐thymocyte globulin induction therapy does not prolong survival after lung transplantation. Journal of Heart &amp; Lung Transplantation2008;27(5):547‐53. [MEDLINE: 18442722] HartwigMG , SnyderLD , AppelJZ , SimsirS , LinSS , PalmerSM , et al. Rabbit antithymocyte globulin induction therapy for lung transplantation does not affect long‐term allograft function or survival [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81‐2. PalmerSM , MirallesAP , LawrenceCM , GaynorJW , DavisRD , TapsonVF . Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study. Chest1999;116(1):127‐33. [MEDLINE: 10424515] ">Hartvig 2008</a> reported no significant difference in the number of patients diagnosed with cancer between the polyclonal T‐cell antibody induction group compared with no induction (8/22 (36%) versus 3/22 (14%), (<a href="./references#CD008927-fig-0022" title="">Analysis 2.9</a> (1 study, 44 participants): RR 2.67, 95% CI 0.81 to 8.75). This was confirmed using Fisher's exact test (P = 0.16). The eight malignancies reported in antibody induction group included three non‐small cell lung cancers, one prostate cancer, one squamous cell nasopharynx cancer, and four skin cancers. There were three malignancies reported among control group that included one non‐small cell lung cancer and two skin cancers. </p> </section> <section id="CD008927-sec-0087"> <h5 class="title">Kidney injury requiring haemodialysis</h5> <p>Kidney injury requiring haemodialysis was not reported.</p> </section> </section> <section id="CD008927-sec-0088"> <h4 class="title">Interleukin‐2 receptor antagonist versus no induction</h4> <p><a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> (36 participants) randomised patients to three groups: ATG, daclizumab or no intervention. The 11 patients who received ATG were excluded from the analyses. </p> <section id="CD008927-sec-0089"> <h5 class="title">Mortality</h5> <p><a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> reported no significant difference in the number of deaths among patients who received IL‐2RA compared with those who received no induction therapy (4/15 (27%) versus 4/10 (40%), (<a href="./references#CD008927-fig-0023" title="">Analysis 3.1</a> (1 study, 25 participants): RR 0.67, 95% CI 0.22 to 2.07). This was confirmed using Fisher's exact test (P = 0.67). Analysis showed that trial sequential monitoring boundaries were not broken by the cumulative Z‐curve, and the required information size of 1131 patients was not achieved. </p> </section> <section id="CD008927-sec-0090"> <h5 class="title">Acute rejection</h5> <p><a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> reported no significant difference in the number of patients experiencing at least one episode of rejection between those treated with IL‐2RA compared with no induction (8/15 (53%) versus 5/10 (50%), (<a href="./references#CD008927-fig-0024" title="">Analysis 3.2</a> (1 study, 25 participants): RR 1.07, 95% CI 0.49 to 2.33). This was confirmed using Fisher's exact test (P = 1.0). Analysis showed that trial sequential monitoring boundaries were not broken by the cumulative Z‐curve, and the required information size of 778 patients was not achieved. </p> </section> <section id="CD008927-sec-0091"> <h5 class="title">Adverse events</h5> <p>Adverse events were not reported.</p> </section> <section id="CD008927-sec-0092"> <h5 class="title">Quality of life</h5> <p>Quality of life measures were not reported.</p> </section> <section id="CD008927-sec-0093"> <h5 class="title">Infection</h5> <p>Infection rates were not reported.</p> <section id="CD008927-sec-0094"> <h6 class="title">Pneumonia (viral, bacterial, or fungal)</h6> <p><a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> reported no significant difference in the number of patients with pneumonia between those treated with IL‐2RA compared with no induction (10/15 (67%) versus 10/10 (100%), (<a href="./references#CD008927-fig-0025" title="">Analysis 3.3</a> (1 study, 25 participants): RR 0.69, 95% CI 0.47 to 1.00). This was confirmed using Fisher's exact test (P = 0.06). </p> </section> <section id="CD008927-sec-0095"> <h6 class="title">Cytomegalovirus infection</h6> <p><a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> reported no significant difference in the number of patients with cytomegalovirus infection between those treated with IL‐2RA compared with no induction (6/15 (40%) versus 5/10 (50%), (<a href="./references#CD008927-fig-0026" title="">Analysis 3.4</a> (1 study, 25 participants): RR 0.80, 95% CI 0.33 to 1.92). This was confirmed using Fisher's exact test (P = 0.70). </p> </section> </section> <section id="CD008927-sec-0096"> <h5 class="title">Bronchiolitis obliterans syndrome</h5> <p><a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> reported no significant difference in the number of patients with bronchiolitis obliterans syndrome between those treated with IL‐2RA compared with no induction (2/15 (13%) versus 4/10 (40%), (<a href="./references#CD008927-fig-0027" title="">Analysis 3.5</a> (1 study, 25 participants): RR 0.33, 95% CI 0.07 to 1.49). This was confirmed using Fisher's exact test (P = 0.18). </p> </section> <section id="CD008927-sec-0097"> <h5 class="title">Post‐transplantation lymphoproliferative disease</h5> <p>PTLD was not reported.</p> </section> <section id="CD008927-sec-0098"> <h5 class="title">Cancer</h5> <p>Cancers were not reported.</p> </section> <section id="CD008927-sec-0099"> <h5 class="title">Kidney injury requiring haemodialysis</h5> <p>Kidney injury requiring haemodialysis was not reported.</p> </section> </section> <section id="CD008927-sec-0100"> <h4 class="title">Polyclonal T‐cell antibody versus muromonab‐CD3</h4> <p><a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a> (64 participants) compared ATG versus muromonab‐CD3. </p> <section id="CD008927-sec-0101"> <h5 class="title">Mortality</h5> <p><a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a> did not report sufficient mortality data to enable statistical analysis. Two year survival for the entire cohort was 68%, with no differences observed in survival among the three induction groups: the ATG and muromonab‐CD3 groups (both of which were randomised), and non‐randomised daclizumab group. </p> </section> <section id="CD008927-sec-0102"> <h5 class="title">Acute rejection</h5> <p>Acute rejection was not sufficiently reported to enable statistical analysis. <a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a> reported that there was no difference in freedom from acute rejection episodes of grade A2 or greater among the three groups (randomised ATG and muromonab‐CD3 groups; non‐randomised daclizumab group). </p> </section> <section id="CD008927-sec-0103"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a> reported drug‐specific adverse effects were more common in the ATG group compared with the muromonab‐CD3 group (25/34 (74%) versus 12/30 (40%), (<a href="./references#CD008927-fig-0028" title="">Analysis 4.1</a> (1 study, 64 participants): RR 1.84, 95% CI 1.13 to 2.98). This was confirmed using Fisher's exact test (P = 0.01). Cytokine release syndrome occurred in 12/30 (40%) patients in the muromonab‐CD3 group, among whom it was associated with hypoxia (5/30, 17%), hypotension (5/30, 17%), and rigor (1/30, 3%). Thrombocytopenia occurred in 25/34 (74%) patients in the ATG group. </p> </section> <section id="CD008927-sec-0104"> <h5 class="title">Quality of life</h5> <p>Quality of life measures were not reported.</p> </section> <section id="CD008927-sec-0105"> <h5 class="title">Infection</h5> <p><a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a> reported no significant difference in the number of infections between patients treated with ATG compared with muromonab‐CD3 (25/34 (74%) versus 23/30 (77%), (<a href="./references#CD008927-fig-0029" title="">Analysis 4.2</a> (1 study, 64 participants): RR 0.96, 95% CI 0.72 to 1.27). This was confirmed using Fisher's exact test (P = 1.0). </p> <p>The incidences of pneumonia or cytomegalovirus infection were not reported.</p> </section> <section id="CD008927-sec-0106"> <h5 class="title">Bronchiolitis obliterans syndrome</h5> <p><a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a> reported no significant difference in the number of patients with bronchiolitis obliterans syndrome between those treated with ATG compared with muromonab‐CD3 (5/34 (15%) versus 7/30 (23%), (<a href="./references#CD008927-fig-0030" title="">Analysis 4.3</a> (1 study, 64 participants): RR 0.63, 95% CI 0.22 to 1.78). This was confirmed using Fisher's exact test (P = 0.52). </p> </section> <section id="CD008927-sec-0107"> <h5 class="title">Post‐transplantation lymphoproliferative disease</h5> <p><a href="./references#CD008927-bbs2-0001" title="BrockMV , BorjaMC , FerberL , OrensJB , AnzcekRA , KrishnanJ , et al. Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti‐thymocyte globulin, and daclizumab. Journal of Heart &amp; Lung Transplantation2001;20(12):1282‐90. [MEDLINE: 11744411] ">Brock 2001</a> reported no significant difference in the number of patients diagnosed with PTLD between those treated with ATG compared with muromonab‐CD3 (2/34 (6%) versus 2/30 (7%), (<a href="./references#CD008927-fig-0031" title="">Analysis 4.4</a> (1 study, 64 participants): RR 0.88; 95% CI 0.13 to 5.88). This was confirmed using Fisher's exact test (P = 1.0). </p> </section> <section id="CD008927-sec-0108"> <h5 class="title">Cancer</h5> <p>Cancers were not reported.</p> </section> <section id="CD008927-sec-0109"> <h5 class="title">Kidney failure requiring haemodialysis</h5> <p>Kidney failure requiring haemodialysis was not reported.</p> </section> </section> <section id="CD008927-sec-0110"> <h4 class="title">Polyclonal T‐cell antibody versus interleukin‐2 receptor antagonist</h4> <p><a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a> (50 participants) compared ATG versus daclizumab; <a href="./references#CD008927-bbs2-0006" title="SennB , DutlyA , NaefR , SpeichR , WederW , BoehlerA . A single center prospective, randomised trial of basiliximab versus ATG induction therapy in lung transplantation [abstract]. European Respiratory Journal2001;18(Suppl 33):179s. ">Senn 2001</a> (24 participants) compared ATG versus basiliximab; and <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> (36 participants) randomised patients to three groups: ATG, daclizumab or no intervention. The 10 patients in <a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> not receiving T‐cell antibody induction were excluded from the analyses. </p> <section id="CD008927-sec-0111"> <h5 class="title">Mortality</h5> <p>There was no significant differences in the number of deaths between patients treated with ATG induction compared with IL‐2RA induction (7/47 (15%) versus 6/53 (11%), (<a href="./references#CD008927-fig-0032" title="">Analysis 5.1</a> (3 studies, 100 participants): RR 1.41, 95% CI 0.54 to 3.70; I² = 0%). Analysis showed that trial sequential monitoring boundaries were not broken by the cumulative Z‐curve, and the required information size of 5787 patients was not obtained. </p> </section> <section id="CD008927-sec-0112"> <h5 class="title">Acute rejection</h5> <p>There was no significant difference in the number of patients experiencing acute rejection between those treated with polyclonal antibody induction compared with IL‐2RA (25/36 (69%) versus 21/40 (53%), (<a href="./references#CD008927-fig-0033" title="">Analysis 5.2</a> (2 studies, 76 participants): RR 1.35, 95% CI 0.94 to 1.94; I² = 0%). Analysis showed that trial sequential monitoring boundaries were not broken by the cumulative Z‐curve, and the required information size of 698 patients was not obtained. </p> </section> <section id="CD008927-sec-0113"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a> reported that one drug‐related adverse event occurred in the ATG group that involved lymphopenia and thrombocytopenia (<a href="./references#CD008927-fig-0034" title="">Analysis 5.3</a>). ATG infusion was temporarily discontinued. </p> </section> <section id="CD008927-sec-0114"> <h5 class="title">Quality of life</h5> <p>Quality of life measures were not reported.</p> </section> <section id="CD008927-sec-0115"> <h5 class="title">Infection</h5> <p><a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a> reported no significant difference in the number of infections between patients treated with ATG compared with IL‐2RA (20/25 (80%) versus 22/25 (88%), (<a href="./references#CD008927-fig-0035" title="">Analysis 5.4</a> (1 study, 50 participants): RR 0.91, 95% CI 0.71 to 1.16). This was confirmed using Fisher's exact test (P = 0.70). </p> <section id="CD008927-sec-0116"> <h6 class="title">Pneumonia (viral, bacterial, or fungal)</h6> <p><a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a> reported no significant difference in the number of patients with pneumonia between those treated with ATG compared with IL‐2RA (8/11 (73%) versus 10/15 (67%), (<a href="./references#CD008927-fig-0036" title="">Analysis 5.5</a> (1 study, 26 participants): RR 1.09, 95% CI 0.66 to 1.81). This was confirmed using Fisher's exact test (P = 1.0). </p> </section> <section id="CD008927-sec-0117"> <h6 class="title">Cytomegalovirus infection</h6> <p>There was no significant difference in the number of patients with cytomegalovirus infection between those treated with ATG compared with IL‐2RA (10/36 (28%) versus 18/40 (45%), (<a href="./references#CD008927-fig-0037" title="">Analysis 5.6</a> (2 studies, 76 participants): RR 0.69, 95% CI 0.17 to 2.88; I² = 80%). </p> </section> </section> <section id="CD008927-sec-0118"> <h5 class="title">Bronchiolitis obliterans syndrome</h5> <p>There was no significant difference in the number of patients with bronchiolitis obliterans syndrome between those treated with ATG compared with IL‐2RA (4/36 (11%) versus 3/40 (8%), (<a href="./references#CD008927-fig-0038" title="">Analysis 5.7</a> (2 studies, 76 participants): RR 1.70, 95% CI 0.42 to 6.79; I² = 0%). </p> </section> <section id="CD008927-sec-0119"> <h5 class="title">Post‐transplantation lymphoproliferative disease</h5> <p><a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a> reported no significant difference in the number of patients diagnosed with PTLD between those treated with ATG induction and the IL‐2RA induction (1/25 (4%) versus 1/25 (4%), (<a href="./references#CD008927-fig-0039" title="">Analysis 5.8</a> (1 study, 50 participants): RR 1.00, 95% CI 0.07 to 15.12). This was confirmed using Fisher's exact test (P = 1.0). </p> </section> <section id="CD008927-sec-0120"> <h5 class="title">Cancer</h5> <p><a href="./references#CD008927-bbs2-0005" title="MullenJC , DueckA , BentleyMJ , ModryDL , StewartK , LienDC , et al. A randomized controlled trial of daclizumab vs. anti‐thymocyte globulin induction for lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2005;24(2):S81. MullenJC , OreopoulosA , LienDC , BentleyMJ , ModryDL , StewartK , et al. A randomized, controlled trial of daclizumab vs anti‐thymocyte globulin induction for lung transplantation. Journal of Heart &amp; Lung Transplantation2007;26(5):504‐10. [MEDLINE: 17449421] ">Mullen 2007</a> reported no malignancies were seen in either the ATG induction or IL‐2RA induction groups. The only study contributing data for this outcome reported no events, and therefore, meta‐analysis was not undertaken. </p> </section> <section id="CD008927-sec-0121"> <h5 class="title">Kidney failure requiring haemodialysis</h5> <p>Kidney failure requiring haemodialysis was not reported.</p> </section> <section id="CD008927-sec-0122"> <h5 class="title">Subgroup analyses</h5> <p>We performed subgroup analyses on ATG type (rabbit versus horse) compared with IL‐2RA on several outcome measures: mortality, acute rejection, bronchiolitis obliterans syndrome, and cytomegalovirus infection. We found no significant differences between type of ATG when applying the test of interaction regarding mortality, acute rejection and bronchiolitis obliterans syndrome. Horse ATG may be better in preventing cytomegalovirus infection than rabbit ATG (P = 0.03). </p> <p>We conducted subgroup analyses on IL‐2RA type (basiliximab versus daclizumab) compared with ATG on mortality, and found no significant differences between IL‐2RAs when applying the test of interaction. </p> </section> </section> <section id="CD008927-sec-0123"> <h4 class="title">Other subgroup analyses</h4> <p>We were unable to perform planned subgroup analyses on risk of bias (high versus low) because all included studies were assessed as high risk of bias. Likewise, subgroup analysis on timing (early versus late) calcineurin inhibitor initiation could not be undertaken because this outcome was not reported. </p> </section> <section id="CD008927-sec-0124"> <h4 class="title">Assessment of harm in non‐randomised controlled studies</h4> <p>We identified eight non‐RCTs that were assessed for the risk of harm (<a href="./references#CD008927-bbs2-0008" title="BarlowCW , MoonMR , GreenGR , GambergP , TheodoreJ , ReitzBA , et al. Rabbit antithymocyte globulin versus OKT3 induction therapy after heart‐lung and lung transplantation: Effect on survival, rejection, infection, and obliterative bronchiolitis. Transplant International2001;14(4):234‐9. [MEDLINE: 11512056] ">Barlow 2001</a>; <a href="./references#CD008927-bbs2-0009" title="BorroJM , De laTorreM , MiguelezC , FernandezR , GonzalezD , LemosC . Comparative study of basiliximab treatment in lung transplantation. Transplantation Proceedings2005;37(9):3996‐8. [MEDLINE: 16386608] ">Borro 2005</a>; <a href="./references#CD008927-bbs2-0022" title="BurtonCM , AndersenCB , JensenAS , IversenM , MilmanN , BoesgaardS , et al. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti‐thymocyte globulin and daclizumab. Journal of Heart &amp; Lung Transplantation2006;25(6):638‐47. [MEDLINE: 16730569] ">Burton 2006</a>; <a href="./references#CD008927-bbs2-0010" title="GarrityERJr , VillanuevaJ , BhoradeSM , HusainAN , VigneswaranWT . Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation2001;71(6):773‐7. [MEDLINE: 11330541] ">Garrity 2001</a>; <a href="./references#CD008927-bbs2-0029" title="HachemRR , ChakinalaMM , YusenRD , LynchJP , AloushAA , PattersonGA , et al. A comparison of basiliximab and anti‐thymocyte globulin as induction agents after lung transplantation. Journal of Heart &amp; Lung Transplantation2005;24(9):1320‐6. [MEDLINE: 16143251] ">Hachem 2005</a>; <a href="./references#CD008927-bbs2-0014" title="LischkeR , SimonekJ , Davidova R , SchutznerJ , StolzAJ , VojácekJ , et al. Induction therapy in lung transplantation: initial single‐center experience comparing daclizumab and antithymocyte globulin. Transplantation Proceedings2007;39(1):205‐12. [MEDLINE: 17275507] ">Lischke 2007</a>; <a href="./references#CD008927-bbs2-0017" title="vanLoenhoutKC , GrovesSC , GalazkaM , ShermanB , BrittE , GarciaJ , et al. Early outcomes using alemtuzumab induction in lung transplantation. Interactive Cardiovascular &amp; Thoracic Surgery2010;10(2):190‐4. [MEDLINE: 19939852] ">van Loenhout 2010</a>; <a href="./references#CD008927-bbs2-0015" title="MaromEM , ChoiYW , PalmerSM , DeLongDM , StuartMD , McAdamsHP . Reperfusion edema after lung transplantation: effect of daclizumab. Radiology2001;221(2):508‐14. [MEDLINE: 11687697] ">Marom 2001</a>) (<a href="#CD008927-tbl-0005">Table 1</a>). We assessed numbers of patients with infection, cytomegalovirus infection, PTLD, and other adverse effects. Overall, no clear harmful effects were identified regarding comparisons of types of induction therapies, or induction therapy type compared with controls. </p> <div class="table" id="CD008927-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Assessment of harm in non‐randomised controlled studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study groups</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> PTLD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Infection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CMV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Other adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008927-bbs2-0008" title="BarlowCW , MoonMR , GreenGR , GambergP , TheodoreJ , ReitzBA , et al. Rabbit antithymocyte globulin versus OKT3 induction therapy after heart‐lung and lung transplantation: Effect on survival, rejection, infection, and obliterative bronchiolitis. Transplant International2001;14(4):234‐9. [MEDLINE: 11512056] ">Barlow 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Muromonab‐CD3: 38</p> <p>ATG: 25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008927-bbs2-0009" title="BorroJM , De laTorreM , MiguelezC , FernandezR , GonzalezD , LemosC . Comparative study of basiliximab treatment in lung transplantation. Transplantation Proceedings2005;37(9):3996‐8. [MEDLINE: 16386608] ">Borro 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daclizumab: 15</p> <p>Control: 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not observed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fungal</b> </p> <p>Daclizumab: 1 (7%)</p> <p>Control: 2 (15%)</p> <p><b>Bacterial</b> </p> <p>Daclizumab: 4 (27%)</p> <p>Control: 2 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daclizumab: 4 (27%)</p> <p>Control: 5 (38%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not observed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008927-bbs2-0022" title="BurtonCM , AndersenCB , JensenAS , IversenM , MilmanN , BoesgaardS , et al. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti‐thymocyte globulin and daclizumab. Journal of Heart &amp; Lung Transplantation2006;25(6):638‐47. [MEDLINE: 16730569] ">Burton 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 151</p> <p>Daclizumab: 151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 8 (5%)</p> <p>Daclizumab: 2 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008927-bbs2-0010" title="GarrityERJr , VillanuevaJ , BhoradeSM , HusainAN , VigneswaranWT . Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation2001;71(6):773‐7. [MEDLINE: 11330541] ">Garrity 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daclizumab: 27</p> <p>Control: 34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daclizumab: 1 (4%)</p> <p>Control: 1 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fungal</b> </p> <p>Daclizumab: 5 (19%)</p> <p>Control: 5 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daclizumab: 5 (19%)</p> <p>Control: 8 (24%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008927-bbs2-0029" title="HachemRR , ChakinalaMM , YusenRD , LynchJP , AloushAA , PattersonGA , et al. A comparison of basiliximab and anti‐thymocyte globulin as induction agents after lung transplantation. Journal of Heart &amp; Lung Transplantation2005;24(9):1320‐6. [MEDLINE: 16143251] ">Hachem 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 75</p> <p>Basiliximab: 82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 0.53 cases/100 patient‐years</p> <p>Basiliximab: 3 cases/100 patient‐years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CMV‐viraemia</b> </p> <p>ATG: 15.1 episodes/100 patient‐months</p> <p>Basiliximab: 15.6 episodes/100 patient‐months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008927-bbs2-0014" title="LischkeR , SimonekJ , Davidova R , SchutznerJ , StolzAJ , VojácekJ , et al. Induction therapy in lung transplantation: initial single‐center experience comparing daclizumab and antithymocyte globulin. Transplantation Proceedings2007;39(1):205‐12. [MEDLINE: 17275507] ">Lischke 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 12</p> <p>Daclizumab: 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No PTLD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 10 (83%)</p> <p>Daclizumab: 6 (46%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thrombocytopenia</p> <p>ATG: 9 (75%)</p> <p>Daclizumab: 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008927-bbs2-0015" title="MaromEM , ChoiYW , PalmerSM , DeLongDM , StuartMD , McAdamsHP . Reperfusion edema after lung transplantation: effect of daclizumab. Radiology2001;221(2):508‐14. [MEDLINE: 11687697] ">Marom 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daclizumab: 43</p> <p>Control: 43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not observed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008927-bbs2-0017" title="vanLoenhoutKC , GrovesSC , GalazkaM , ShermanB , BrittE , GarciaJ , et al. Early outcomes using alemtuzumab induction in lung transplantation. Interactive Cardiovascular &amp; Thoracic Surgery2010;10(2):190‐4. [MEDLINE: 19939852] ">van Loenhout 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alemtuzumab: 20</p> <p>Control: 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not observed</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ATG ‐ antithymocyte globulin; CMV ‐ cytomegalovirus; PTLD ‐ post‐transplant lymphoproliferative disease </p> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008927-sec-0125" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008927-sec-0125"></div> <section id="CD008927-sec-0126"> <h3 class="title" id="CD008927-sec-0126">Summary of main results</h3> <p>This review identified six studies (278 participants) that assessed the effects of different types of T‐cell antibody induction in lung transplant recipients. All included studies were assessed at high risk of bias. </p> <p>Overall our meta‐analyses did not find any statistically significant differences between any of the randomised groups regarding mortality, acute rejection, infection, pneumonia, cytomegalovirus infection, bronchiolitis obliterans syndrome, PTLD, or cancer. </p> <p>The only study comparing ATG with muromonab‐CD3 seemed to show an increase in adverse events in the ATG group; however, trial sequential analysis could not exclude random error (<a href="./references#CD008927-bbs2-0003" title="ConteJV . The use of daclizumab and anti‐thymocyte globulin in lung transplantation. www.clinicaltrials.gov/ct2/show/NCT00181142 (accessed 1 October 2013). ">Conte 2010</a>). </p> <p>None of the studies reported on quality of life or kidney failure requiring haemodialysis.</p> <p>Findings were confirmed when the fixed‐effect model was applied to the meta‐analyses. The required information size was not obtained in any trial sequential analyses for the primary outcome measures. Absence of evidence however does not necessarily mean absence of effect. </p> </section> <section id="CD008927-sec-0127"> <h3 class="title" id="CD008927-sec-0127">Overall completeness and applicability of evidence</h3> <p>We examined the evidence from six RCTs that investigated the use of T‐cell antibody induction for lung transplant recipients. We were unable to obtain data relating to all pre‐defined outcome measures because they were not all reported in the included studies. </p> <p>Overall, reporting in the included studies was suboptimal: five studies reported adequately on mortality; four on acute rejection; four on infection; and five on bronchiolitis obliterans syndrome. Only two studies reported on drug‐related adverse events. None of the studies reported on quality of life or kidney failure requiring haemodialysis. </p> <p>Not all types of T‐cell antibody induction currently available have been studied in randomised studies. Alemtuzumab for induction after lung transplantation has been introduced during the last decade, and is now used for almost 10% of all lung transplant recipients. However, no evidence from randomised studies regarding alemtuzumab was identified. IL‐2RA were found to be the most commonly used type of induction therapy, used in over 40% of all lung transplant recipients. Nevertheless only one included randomised study with 25 patients investigated the use of IL‐2RA compared with no intervention. A study that compared IL‐2RA with no intervention has been completed, but contact with the investigators indicated that results were not yet available (<a href="./references#CD008927-bbs2-0020" title="WaddellTK . A randomized, double blind, placebo controlled study comparing simulect plus standard immunosuppression to standard immunosuppression alone for the prevention of acute rejection and bronchiolitis obliterans syndrome in bilateral lung and single lung transplant patients. http://www.clinicaltrials.gov/ct2/show/NCT00188825 (accessed 1 October 2013). WaddellTK , BorroJM , RomanA , CarrenoMV , ZurbanoF , SantosF , et al. A double‐blind randomized trial comparing basiliximab to placebo in lung transplantation [abstract]. Journal of Heart &amp; Lung Transplantation2006;25(2 Suppl):S114. ">Waddell 2006</a>). </p> </section> <section id="CD008927-sec-0128"> <h3 class="title" id="CD008927-sec-0128">Quality of the evidence</h3> <p>We conducted this review in accordance with the requirements in <i>The Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008927-bbs2-0034" title="HigginsJP , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) and conducted trial sequential analysis (<a href="./references#CD008927-bbs2-0057" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>; <a href="./references#CD008927-bbs2-0054" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark, 2011. http://www.ctu.dk/tsa/files/tsa_manual.pdf (accessed 1 October 2013). ">TSA 2011</a>). </p> <p>The quality and quantity of available evidence limited our findings and interpretations. Very limited numbers of participants were included in the studies, and hence, risks of random errors potentially explain occasional positive findings in individual studies. Additionally, study participants may not be representative of the general patient population. </p> <p>Follow‐up in five studies was between six months and two years; and eight years in one study. We therefore were unable to elicit evidence relating to longer‐term (greater than two years) effects of T‐cell antibody induction on outcome measures. Long‐term effects in terms of mortality, bronchiolitis obliterans syndrome, infection, and cancer would be particularly valuable. </p> <p>We explored the presence of statistical heterogeneity using the Chi² test and measured heterogeneity using the I² test (<a href="./references#CD008927-bbs2-0033" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [MEDLINE: 12958120] ">Higgins 2003</a>). The Chi² test is low powered in meta‐analyses where studies are small or few in number, as in this review. This means that while a statistically significant result may indicate a problem with heterogeneity, a non‐significant result must not be taken as evidence of homogeneity. To reflect our concern with heterogeneity, we looked at both fixed‐effect and random‐effects models to provide more conservative effect estimates. No differences were seen between fixed‐effect and random‐effects models for any of the primary outcome measures considered in this review. </p> <p>Precision of our results was influenced because many outcomes planned for meta‐analyses includes few patients and events, and thus, have wide confidence intervals around the effect estimate. </p> </section> <section id="CD008927-sec-0129"> <h3 class="title" id="CD008927-sec-0129">Potential biases in the review process</h3> <p>Bias is known to impact on the estimated intervention effect, and studies assessed at high risk of bias tend to overestimate beneficial intervention effects (<a href="./references#CD008927-bbs2-0039" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. [MEDLINE: 11730399] ">Kjaergard 2001</a>; <a href="./references#CD008927-bbs2-0042" title="MoherD , PhamB , JonesA , CookDJ , JadadAR , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet1998;352(9128):609‐13. [MEDLINE: 9746022] ">Moher 1998</a>; <a href="./references#CD008927-bbs2-0049" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. [MEDLINE: 7823387] ">Schulz 1995</a>). Of the six included studies, reporting was suboptimal: allocation concealment was not reported in any of the included studies; adequate allocation sequence generation was reported by one study; participant blinding was reported by one study; one was blinded for the pathologist who examined transbronchial biopsies for rejection. Reporting of incomplete outcome data was adequate in four studies, and all reported on reasonably expected outcome measures. Four studies appeared to be free of other components that could put the study at risk of bias, and one was unclear. Accordingly, all studies were considered to be at high risk of bias, and estimated intervention effects may therefore be due to systematic errors. </p> <p>The risk of random error is higher among data from small studies. Studies need to be sufficiently large to reduce the risk of random error and increase the chance of observing a true intervention effect (<a href="./references#CD008927-bbs2-0057" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology2008;61(1):64‐75. [MEDLINE: 18083463] ">Wetterslev 2008</a>). To address these issues, we also conducted trial sequential analysis. Trial sequential analysis is a statistical method that assesses risk of random error caused by sparse data and formal or informal repetitive testing of accumulated data. Trial sequential analysis of outcome measures in this review showed that the required information size was not reached. Hence, we were unable to determine whether there may be beneficial or harmful effects associated with the use of antibody induction or relative superiority of any antibody over another. </p> </section> <section id="CD008927-sec-0130"> <h3 class="title" id="CD008927-sec-0130">Agreements and disagreements with other studies or reviews</h3> <p>Data from the International Society for Heart and Lung Transplantation registry, which are based on nearly 11,000 lung recipients who received lung transplants between January 2000 and June 2009, showed that T‐cell antibody induction appeared to have a favourable effect on survival (<a href="./references#CD008927-bbs2-0025" title="ChristieJD , EdwardsLB , KucheryavayaAY , BendenC , DobbelsF , KirkR , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐eighth Adult Lung and Heart‐Lung Transplant Report‐‐2011. Journal of Heart &amp; Lung Transplantation2011;30(10):1104‐22. [MEDLINE: 21962018] ">Christie 2011</a>). Due to the observational nature of these data, findings should be interpreted with caution because they were not adjusted for diagnosis category, age, centre, or other potentially confounding factors. The reduced mortality observed in the registry data could not be confirmed in our meta‐analyses. Furthermore, the registry data showed that compared with other types of induction therapy, IL‐2RA induction was associated with a lower incidence of acute rejection during the first year following transplantation (<a href="./references#CD008927-bbs2-0025" title="ChristieJD , EdwardsLB , KucheryavayaAY , BendenC , DobbelsF , KirkR , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐eighth Adult Lung and Heart‐Lung Transplant Report‐‐2011. Journal of Heart &amp; Lung Transplantation2011;30(10):1104‐22. [MEDLINE: 21962018] ">Christie 2011</a>). The lower rejection rates among lung transplant recipients who were treated with IL‐2RA induction therapy appeared to be similar across age groups, despite apparent differences in rejection rates with other induction strategies by recipient age category (<a href="./references#CD008927-bbs2-0025" title="ChristieJD , EdwardsLB , KucheryavayaAY , BendenC , DobbelsF , KirkR , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐eighth Adult Lung and Heart‐Lung Transplant Report‐‐2011. Journal of Heart &amp; Lung Transplantation2011;30(10):1104‐22. [MEDLINE: 21962018] ">Christie 2011</a>). </p> <p>Using data from the same registry, <a href="./references#CD008927-bbs2-0031" title="HachemRR , EdwardsLB , YusenRD , ChakinalaMM , Alexander PattersonG , TrulockEP . The impact of induction on survival after lung transplantation: an analysis of the International Society for Heart and Lung Transplantation Registry. Clinical Transplantation2008;22(5):603‐8. [MEDLINE: 18435784] ">Hachem 2008</a> found that IL‐2RA induction therapy for single and double lung transplant recipients and induction with ATG for double lung transplant recipients was associated with lower mortality. We were unable to confirm this reduction in mortality and acute rejection associated with the use of IL‐2RA in our meta‐analyses. </p> <p>Large cohort studies conducted by <a href="./references#CD008927-bbs2-0022" title="BurtonCM , AndersenCB , JensenAS , IversenM , MilmanN , BoesgaardS , et al. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti‐thymocyte globulin and daclizumab. Journal of Heart &amp; Lung Transplantation2006;25(6):638‐47. [MEDLINE: 16730569] ">Burton 2006</a> and <a href="./references#CD008927-bbs2-0029" title="HachemRR , ChakinalaMM , YusenRD , LynchJP , AloushAA , PattersonGA , et al. A comparison of basiliximab and anti‐thymocyte globulin as induction agents after lung transplantation. Journal of Heart &amp; Lung Transplantation2005;24(9):1320‐6. [MEDLINE: 16143251] ">Hachem 2005</a> compared ATG and IL‐2RA. <a href="./references#CD008927-bbs2-0022" title="BurtonCM , AndersenCB , JensenAS , IversenM , MilmanN , BoesgaardS , et al. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti‐thymocyte globulin and daclizumab. Journal of Heart &amp; Lung Transplantation2006;25(6):638‐47. [MEDLINE: 16730569] ">Burton 2006</a> compared induction using rabbit ATG with daclizumab induction in 335 lung transplant recipients. Patients who received ATG had a statistically significant lower incidence of acute rejection compared with patients who were treated with daclizumab (<a href="./references#CD008927-bbs2-0022" title="BurtonCM , AndersenCB , JensenAS , IversenM , MilmanN , BoesgaardS , et al. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti‐thymocyte globulin and daclizumab. Journal of Heart &amp; Lung Transplantation2006;25(6):638‐47. [MEDLINE: 16730569] ">Burton 2006</a>). <a href="./references#CD008927-bbs2-0029" title="HachemRR , ChakinalaMM , YusenRD , LynchJP , AloushAA , PattersonGA , et al. A comparison of basiliximab and anti‐thymocyte globulin as induction agents after lung transplantation. Journal of Heart &amp; Lung Transplantation2005;24(9):1320‐6. [MEDLINE: 16143251] ">Hachem 2005</a> compared induction using horse ATG with basiliximab induction in 157 lung transplant recipients. Lung transplant recipients with severe ischaemia‐reperfusion injury after transplantation, and those who were serologically mismatched for cytomegalovirus, were excluded from ATG induction therapy (<a href="./references#CD008927-bbs2-0029" title="HachemRR , ChakinalaMM , YusenRD , LynchJP , AloushAA , PattersonGA , et al. A comparison of basiliximab and anti‐thymocyte globulin as induction agents after lung transplantation. Journal of Heart &amp; Lung Transplantation2005;24(9):1320‐6. [MEDLINE: 16143251] ">Hachem 2005</a>). Acute rejection and bronchiolitis obliterans syndrome occurred less often in the ATG group compared with the basiliximab group (<a href="./references#CD008927-bbs2-0029" title="HachemRR , ChakinalaMM , YusenRD , LynchJP , AloushAA , PattersonGA , et al. A comparison of basiliximab and anti‐thymocyte globulin as induction agents after lung transplantation. Journal of Heart &amp; Lung Transplantation2005;24(9):1320‐6. [MEDLINE: 16143251] ">Hachem 2005</a>). </p> <p>Findings similar to those reported by <a href="./references#CD008927-bbs2-0022" title="BurtonCM , AndersenCB , JensenAS , IversenM , MilmanN , BoesgaardS , et al. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti‐thymocyte globulin and daclizumab. Journal of Heart &amp; Lung Transplantation2006;25(6):638‐47. [MEDLINE: 16730569] ">Burton 2006</a> and <a href="./references#CD008927-bbs2-0029" title="HachemRR , ChakinalaMM , YusenRD , LynchJP , AloushAA , PattersonGA , et al. A comparison of basiliximab and anti‐thymocyte globulin as induction agents after lung transplantation. Journal of Heart &amp; Lung Transplantation2005;24(9):1320‐6. [MEDLINE: 16143251] ">Hachem 2005</a> showing less rejection associated with ATG compared with IL‐2RA were not found when data from the International Society for Heart and Lung Transplantation registry were analysed (<a href="./references#CD008927-bbs2-0025" title="ChristieJD , EdwardsLB , KucheryavayaAY , BendenC , DobbelsF , KirkR , et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty‐eighth Adult Lung and Heart‐Lung Transplant Report‐‐2011. Journal of Heart &amp; Lung Transplantation2011;30(10):1104‐22. [MEDLINE: 21962018] ">Christie 2011</a>). Likewise, our meta‐analyses could not confirm these findings. </p> <p>Traditionally, immunosuppressive therapy for lung transplantation has gained much knowledge from the reported experiences of other types of organ transplantation. A Cochrane review by <a href="./references#CD008927-bbs2-0056" title="WebsterAC , RusterLP , McGeeR , MathesonSL , HigginsGY , WillisNS , et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD003897.pub3] ">Webster 2010</a> that included 71 studies reporting data on 10,537 patients investigated the use of IL‐2RA for kidney transplant recipients. <a href="./references#CD008927-bbs2-0056" title="WebsterAC , RusterLP , McGeeR , MathesonSL , HigginsGY , WillisNS , et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD003897.pub3] ">Webster 2010</a> found that compared with placebo, IL‐2RA reduced graft loss, including death, by 25% at six months and one year, but not beyond (<a href="./references#CD008927-bbs2-0056" title="WebsterAC , RusterLP , McGeeR , MathesonSL , HigginsGY , WillisNS , et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD003897.pub3] ">Webster 2010</a>). Furthermore, compared with placebo, IL‐2RA reduced biopsy‐proven acute rejection (RR 0.75, 95% CI 0.58 to 0.98) and cytomegalovirus disease (RR 0.81, 95% CI 0.68 to 0.97) in kidney transplant recipients (<a href="./references#CD008927-bbs2-0056" title="WebsterAC , RusterLP , McGeeR , MathesonSL , HigginsGY , WillisNS , et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD003897.pub3] ">Webster 2010</a>). Where IL‐2RA was compared with ATG in kidney transplant recipients, biopsy‐proven acute rejection at one year was increased in the IL‐2RA group by 30%, but incidence of malignancies (RR 0.25, 95% CI 0.07 to 0.87) and cytomegalovirus disease (RR 0.68, 95 % CI 0.50 to 0.97) were reduced when IL‐2RA was compared with ATG (<a href="./references#CD008927-bbs2-0056" title="WebsterAC , RusterLP , McGeeR , MathesonSL , HigginsGY , WillisNS , et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD003897.pub3] ">Webster 2010</a>). </p> <p>In a recent Cochrane review (<a href="./references#CD008927-bbs2-0045" title="PenningaL , WettergrenA , WilsonCH , ChanAW , SteinbrüchelDA , GluudC . Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD010253] ">Penninga 2012a</a>), we compared antibody induction versus no induction for liver transplant recipients in 17 studies with a total of 1951 patients. Antibody induction may reduce acute rejection when compared with no antibody induction. No other clear benefits or harms were associated with the use of antibody induction compared with no antibody induction (<a href="./references#CD008927-bbs2-0045" title="PenningaL , WettergrenA , WilsonCH , ChanAW , SteinbrüchelDA , GluudC . Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD010253] ">Penninga 2012a</a>). </p> <p>Furthermore, we reported the use of antibody induction therapy compared with corticosteroid for liver transplant recipients. Our review included 10 studies that presented data from 1589 participants (<a href="./references#CD008927-bbs2-0046" title="PenningaL , WettergrenA , WilsonCH , ChanA‐W , SteinbrüchelDA , GluudC . Antibody induction versus corticosteroid induction for liver transplant recipients. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD010252] ">Penninga 2012b</a>). Antibody induction seems to reduce diabetes mellitus and may reduce cytomegalovirus infection when compared with corticosteroid induction. No other clear benefits or harms were associated with the use of antibody induction compared with corticosteroid induction (<a href="./references#CD008927-bbs2-0046" title="PenningaL , WettergrenA , WilsonCH , ChanA‐W , SteinbrüchelDA , GluudC . Antibody induction versus corticosteroid induction for liver transplant recipients. Cochrane Database of Systematic Reviews2012, Issue 11. [DOI: 10.1002/14651858.CD010252] ">Penninga 2012b</a>). </p> <p>Our earlier Cochrane review (<a href="./references#CD008927-bbs2-0044" title="PenningaL , MøllerCH , GustafssonF , GluudC , SteinbrüchelDA . Immunosuppressive T‐cell antibody induction therapy for heart transplant recipients. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD008842] ">Penninga 2010</a>) investigated the use of antibody induction for heart transplant recipients. This review included 22 studies that presented data from 1427 participants. This review demonstrated that compared with placebo, IL‐2RA induction may reduce acute rejection when meta‐analysed using a fixed‐effect model; however, this effect did not occur using a random‐effects model. Polyclonal antibodies may be superior in reducing acute rejection compared with IL‐2RA for heart transplant recipients, but not for other outcomes. The review found no significant differences regarding mortality, infections, and malignancy (<a href="./references#CD008927-bbs2-0044" title="PenningaL , MøllerCH , GustafssonF , GluudC , SteinbrüchelDA . Immunosuppressive T‐cell antibody induction therapy for heart transplant recipients. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD008842] ">Penninga 2010</a>). </p> <p>Overall, potential advantages of some antibody types concerning certain outcome measures in other solid organ transplant recipients were not found in lung transplant recipients. Whether this is due to the limited numbers of patients and events, systematic errors, design errors, or organ‐specific differences is currently unclear. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008927-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD008927-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#CD008927-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD008927-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#CD008927-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD008927-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#CD008927-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Any induction versus no induction; mortality: trial sequential analysis of the effect of induction versus no induction on mortality based on three studies (140 participants). The required information size of 935 patients was calculated based on type I error of 5%, type II error of 20%, risk reduction of 20%, and information size was adjusted for heterogeneity (I² = 0%)" data-id="CD008927-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Any induction versus no induction; mortality: trial sequential analysis of the effect of induction versus no induction on mortality based on three studies (140 participants). The required information size of 935 patients was calculated based on type I error of 5%, type II error of 20%, risk reduction of 20%, and information size was adjusted for heterogeneity (I² = 0%) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#CD008927-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Induction versus no induction, Outcome 1 Mortality." data-id="CD008927-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Induction versus no induction, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Induction versus no induction, Outcome 2 Acute rejection grade II or higher." data-id="CD008927-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Induction versus no induction, Outcome 2 Acute rejection grade II or higher. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Induction versus no induction, Outcome 3 Adverse events." data-id="CD008927-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Induction versus no induction, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Induction versus no induction, Outcome 4 Infection." data-id="CD008927-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Induction versus no induction, Outcome 4 Infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Induction versus no induction, Outcome 5 Pneumonia." data-id="CD008927-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Induction versus no induction, Outcome 5 Pneumonia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Induction versus no induction, Outcome 6 CMV infection." data-id="CD008927-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Induction versus no induction, Outcome 6 CMV infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Induction versus no induction, Outcome 7 Bronchiolitis obliterans syndrome." data-id="CD008927-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Induction versus no induction, Outcome 7 Bronchiolitis obliterans syndrome.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Induction versus no induction, Outcome 8 Post‐transplantation lymphoproliferative disease (PTLD)." data-id="CD008927-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Induction versus no induction, Outcome 8 Post‐transplantation lymphoproliferative disease (PTLD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Induction versus no induction, Outcome 9 Cancer." data-id="CD008927-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Induction versus no induction, Outcome 9 Cancer.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal antibody versus no induction, Outcome 1 Mortality." data-id="CD008927-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal antibody versus no induction, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal antibody versus no induction, Outcome 2 Acute rejection grade II or higher." data-id="CD008927-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal antibody versus no induction, Outcome 2 Acute rejection grade II or higher. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal antibody versus no induction, Outcome 3 Adverse events." data-id="CD008927-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal antibody versus no induction, Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal antibody versus no induction, Outcome 4 Infection." data-id="CD008927-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal antibody versus no induction, Outcome 4 Infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal antibody versus no induction, Outcome 5 Pneumonia." data-id="CD008927-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal antibody versus no induction, Outcome 5 Pneumonia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal antibody versus no induction, Outcome 6 CMV infection." data-id="CD008927-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal antibody versus no induction, Outcome 6 CMV infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal antibody versus no induction, Outcome 7 Bronchiolitis obliterans syndrome." data-id="CD008927-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal antibody versus no induction, Outcome 7 Bronchiolitis obliterans syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal antibody versus no induction, Outcome 8 Post‐transplantation lymphoproliferative disease (PTLD)." data-id="CD008927-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal antibody versus no induction, Outcome 8 Post‐transplantation lymphoproliferative disease (PTLD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Polyclonal antibody versus no induction, Outcome 9 Cancer." data-id="CD008927-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Polyclonal antibody versus no induction, Outcome 9 Cancer.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Interleukin‐2 receptor antagonist versus no induction, Outcome 1 Mortality." data-id="CD008927-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Interleukin‐2 receptor antagonist versus no induction, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Interleukin‐2 receptor antagonist versus no induction, Outcome 2 Acute rejection." data-id="CD008927-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Interleukin‐2 receptor antagonist versus no induction, Outcome 2 Acute rejection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Interleukin‐2 receptor antagonist versus no induction, Outcome 3 Pneumonia." data-id="CD008927-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Interleukin‐2 receptor antagonist versus no induction, Outcome 3 Pneumonia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Interleukin‐2 receptor antagonist versus no induction, Outcome 4 CMV infection." data-id="CD008927-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Interleukin‐2 receptor antagonist versus no induction, Outcome 4 CMV infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Interleukin‐2 receptor antagonist versus no induction, Outcome 5 Bronchiolitis obliterans syndrome." data-id="CD008927-fig-0027" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Interleukin‐2 receptor antagonist versus no induction, Outcome 5 Bronchiolitis obliterans syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Polyclonal antibody versus muromonab‐CD3, Outcome 1 Adverse events." data-id="CD008927-fig-0028" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Polyclonal antibody versus muromonab‐CD3, Outcome 1 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Polyclonal antibody versus muromonab‐CD3, Outcome 2 Infection." data-id="CD008927-fig-0029" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Polyclonal antibody versus muromonab‐CD3, Outcome 2 Infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Polyclonal antibody versus muromonab‐CD3, Outcome 3 Bronchiolitis obliterans syndrome." data-id="CD008927-fig-0030" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Polyclonal antibody versus muromonab‐CD3, Outcome 3 Bronchiolitis obliterans syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Polyclonal antibody versus muromonab‐CD3, Outcome 4 Post‐transplantation lymphoproliferative disease (PTLD)." data-id="CD008927-fig-0031" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Polyclonal antibody versus muromonab‐CD3, Outcome 4 Post‐transplantation lymphoproliferative disease (PTLD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 1 Mortality." data-id="CD008927-fig-0032" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 1 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 2 Acute rejection." data-id="CD008927-fig-0033" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 2 Acute rejection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 3 Adverse events." data-id="CD008927-fig-0034" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 3 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 4 Infection." data-id="CD008927-fig-0035" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 4 Infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 5 Pneumonia." data-id="CD008927-fig-0036" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 5 Pneumonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 6 CMV infection." data-id="CD008927-fig-0037" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 6 CMV infection. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 7 Bronchiolitis obliterans syndrome." data-id="CD008927-fig-0038" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 7 Bronchiolitis obliterans syndrome. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 8 Post‐transplantation lymphoproliferative disease (PTLD)." data-id="CD008927-fig-0039" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 8 Post‐transplantation lymphoproliferative disease (PTLD). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008927-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/urn:x-wiley:14651858:media:CD008927:CD008927-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_t/tCD008927-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 9 Cancer." data-id="CD008927-fig-0040" src="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 Polyclonal antibody versus interleukin‐2 receptor antagonist, Outcome 9 Cancer. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/media/CDSR/CD008927/image_n/nCD008927-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008927-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">T‐cell antibody induction compared with no antibody induction for lung transplant recipients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>T‐cell antibody induction compared with no antibody induction for lung transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> lung transplant recipients<br/> <b>Settings:</b> patients with end‐stage lung failure who underwent lung transplantation<br/> <b>Intervention:</b> antibody induction<br/> <b>Comparison:</b> no antibody induction </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> No antibody induction</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Antibody induction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b> <br/> Follow‐up: 2 to 8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.99</b> <br/> (0.69 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>140 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>448 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>444 per 1000</b> <br/> (309 to 632) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>396 per 1000</b> <br/> (276 to 564) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Acute rejection grade II or higher</b> <br/> Follow‐up: 2 to 8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.66</b> <br/> (0.43 to 1.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>140 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>483 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>319 per 1000</b> <br/> (208 to 492) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>330 per 1000</b> <br/> (215 to 510) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Infection</b> <br/> Follow‐up: 2 to 8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.4</b> <br/> (0.97 to 2.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>104 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>458 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>642 per 1000</b> <br/> (445 to 921) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>458 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>641 per 1000</b> <br/> (444 to 921) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Bronchiolitis obliterans syndrome</b> <br/> Follow‐up: 2 to 8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.77</b> <br/> (0.55 to 1.09) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>140 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>534 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>412 per 1000</b> <br/> (294 to 583) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b> <br/> (220 to 436) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ All studies were assessed to be at high risk of bias using the Cochrane risk of bias tool </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">T‐cell antibody induction compared with no antibody induction for lung transplant recipients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#CD008927-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008927-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Polyclonal T‐cell antibody compared with no antibody induction for lung transplant recipients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Polyclonal T‐cell antibody compared with no antibody induction for lung transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> lung transplant recipients<br/> <b>Settings:</b> patients with end‐stage lung disease who underwent lung transplantation<br/> <b>Intervention:</b> polyclonal antibody<br/> <b>Comparison:</b> no antibody induction </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> No antibody induction</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Polyclonal antibody</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b> <br/> Follow‐up: 2 to 8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.02</b> <br/> (0.71 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>125 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>448 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>457 per 1000</b> <br/> (318 to 659) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>408 per 1000</b> <br/> (284 to 588) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Acute rejection grade II or higher</b> <br/> Follow‐up: 2 to 8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.68</b> <br/> (0.44 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>125 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>483 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>328 per 1000</b> <br/> (212 to 502) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>340 per 1000</b> <br/> (220 to 520) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Infection</b> <br/> Follow‐up: 2 to 8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.4</b> <br/> (0.97 to 2.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>104 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>458 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>642 per 1000</b> <br/> (445 to 921) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>458 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>641 per 1000</b> <br/> (444 to 921) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Bronchiolitis obliterans syndrome</b> <br/> Follow‐up: 2 to 8 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.81</b> <br/> (0.57 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>125 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>534 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>433 per 1000</b> <br/> (305 to 620) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>324 per 1000</b> <br/> (228 to 464) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ All studies were assessed to be at high risk of bias using the Cochrane risk of bias tool </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Polyclonal T‐cell antibody compared with no antibody induction for lung transplant recipients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#CD008927-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008927-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">IL‐2 receptor antagonist induction compared with no antibody induction for lung transplant recipients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>IL‐2 receptor antagonist induction compared with no antibody induction for lung transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> lung transplant recipients<br/> <b>Settings:</b> patients with end‐stage lung disease who underwent lung transplantation<br/> <b>Intervention:</b> interleukin‐2 receptor antagonist (IL‐2RA) induction<br/> <b>Comparison:</b> no antibody induction </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> No antibody induction</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> IL‐2RA induction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b> <br/> Follow‐up: mean 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.67</b> <br/> (0.22 to 2.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>25 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b> <br/> (88 to 828) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>268 per 1000</b> <br/> (88 to 828) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Acute rejection</b> <br/> Follow‐up: mean 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.07</b> <br/> (0.49 to 2.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>25 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>535 per 1000</b> <br/> (245 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>535 per 1000</b> <br/> (245 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Bronchiolitis obliterans syndrome</b> <br/> Follow‐up: mean 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.33</b> <br/> (0.07 to 1.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>25 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b> <br/> (28 to 596) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>132 per 1000</b> <br/> (28 to 596) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ All studies were assessed to be at high risk of bias using the Cochrane risk of bias tool </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">IL‐2 receptor antagonist induction compared with no antibody induction for lung transplant recipients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#CD008927-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008927-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Polyclonal T‐cell antibody induction compared with interleukin‐2 receptor antagonist induction for lung transplant recipients</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Polyclonal T‐cell antibody induction compared with IL‐2RA induction for lung transplant recipients</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> lung transplant recipients<br/> <b>Settings:</b> patients with end‐stage lung disease who underwent lung transplantation<br/> <b>Intervention:</b> polyclonal antibody induction<br/> <b>Comparison:</b> interleukin‐2 receptor antagonist (IL‐2RA) induction </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> IL‐2RA induction</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Polyclonal antibody induction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mortality</b> <br/> Follow‐up: 0.5 to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.41</b> <br/> (0.55 to 3.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>100 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>113 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> <br/> (62 to 412) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>109 per 1000</b> <br/> (42 to 280) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Acute rejection</b> <br/> Follow‐up: 1 to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.33</b> <br/> (0.93 to 1.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>76 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>525 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>698 per 1000</b> <br/> (488 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>527 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>701 per 1000</b> <br/> (490 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Infection</b> <br/> Follow‐up: mean 1 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.91</b> <br/> (0.71 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>50 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>880 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>801 per 1000</b> <br/> (625 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>880 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>801 per 1000</b> <br/> (625 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Bronchiolitis obliterans syndrome</b> <br/> Follow‐up: 1 to 2 years </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.66</b> <br/> (0.42 to 6.53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>76 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b>¹ </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>75 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>124 per 1000</b> <br/> (31 to 490) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>144 per 1000</b> <br/> (37 to 568) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹ All studies were assessed to be at high risk of bias using the Cochrane risk of bias tool </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Polyclonal T‐cell antibody induction compared with interleukin‐2 receptor antagonist induction for lung transplant recipients</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#CD008927-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008927-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Assessment of harm in non‐randomised controlled studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study groups</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> PTLD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Infection</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CMV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Other adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008927-bbs2-0008" title="BarlowCW , MoonMR , GreenGR , GambergP , TheodoreJ , ReitzBA , et al. Rabbit antithymocyte globulin versus OKT3 induction therapy after heart‐lung and lung transplantation: Effect on survival, rejection, infection, and obliterative bronchiolitis. Transplant International2001;14(4):234‐9. [MEDLINE: 11512056] ">Barlow 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Muromonab‐CD3: 38</p> <p>ATG: 25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008927-bbs2-0009" title="BorroJM , De laTorreM , MiguelezC , FernandezR , GonzalezD , LemosC . Comparative study of basiliximab treatment in lung transplantation. Transplantation Proceedings2005;37(9):3996‐8. [MEDLINE: 16386608] ">Borro 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daclizumab: 15</p> <p>Control: 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not observed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fungal</b> </p> <p>Daclizumab: 1 (7%)</p> <p>Control: 2 (15%)</p> <p><b>Bacterial</b> </p> <p>Daclizumab: 4 (27%)</p> <p>Control: 2 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daclizumab: 4 (27%)</p> <p>Control: 5 (38%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not observed</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008927-bbs2-0022" title="BurtonCM , AndersenCB , JensenAS , IversenM , MilmanN , BoesgaardS , et al. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti‐thymocyte globulin and daclizumab. Journal of Heart &amp; Lung Transplantation2006;25(6):638‐47. [MEDLINE: 16730569] ">Burton 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 151</p> <p>Daclizumab: 151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 8 (5%)</p> <p>Daclizumab: 2 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008927-bbs2-0010" title="GarrityERJr , VillanuevaJ , BhoradeSM , HusainAN , VigneswaranWT . Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation2001;71(6):773‐7. [MEDLINE: 11330541] ">Garrity 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daclizumab: 27</p> <p>Control: 34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daclizumab: 1 (4%)</p> <p>Control: 1 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fungal</b> </p> <p>Daclizumab: 5 (19%)</p> <p>Control: 5 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daclizumab: 5 (19%)</p> <p>Control: 8 (24%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008927-bbs2-0029" title="HachemRR , ChakinalaMM , YusenRD , LynchJP , AloushAA , PattersonGA , et al. A comparison of basiliximab and anti‐thymocyte globulin as induction agents after lung transplantation. Journal of Heart &amp; Lung Transplantation2005;24(9):1320‐6. [MEDLINE: 16143251] ">Hachem 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 75</p> <p>Basiliximab: 82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 0.53 cases/100 patient‐years</p> <p>Basiliximab: 3 cases/100 patient‐years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>CMV‐viraemia</b> </p> <p>ATG: 15.1 episodes/100 patient‐months</p> <p>Basiliximab: 15.6 episodes/100 patient‐months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008927-bbs2-0014" title="LischkeR , SimonekJ , Davidova R , SchutznerJ , StolzAJ , VojácekJ , et al. Induction therapy in lung transplantation: initial single‐center experience comparing daclizumab and antithymocyte globulin. Transplantation Proceedings2007;39(1):205‐12. [MEDLINE: 17275507] ">Lischke 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 12</p> <p>Daclizumab: 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No PTLD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ATG: 10 (83%)</p> <p>Daclizumab: 6 (46%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thrombocytopenia</p> <p>ATG: 9 (75%)</p> <p>Daclizumab: 0 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008927-bbs2-0015" title="MaromEM , ChoiYW , PalmerSM , DeLongDM , StuartMD , McAdamsHP . Reperfusion edema after lung transplantation: effect of daclizumab. Radiology2001;221(2):508‐14. [MEDLINE: 11687697] ">Marom 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daclizumab: 43</p> <p>Control: 43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not observed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008927-bbs2-0017" title="vanLoenhoutKC , GrovesSC , GalazkaM , ShermanB , BrittE , GarciaJ , et al. Early outcomes using alemtuzumab induction in lung transplantation. Interactive Cardiovascular &amp; Thoracic Surgery2010;10(2):190‐4. [MEDLINE: 19939852] ">van Loenhout 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alemtuzumab: 20</p> <p>Control: 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not observed</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>ATG ‐ antithymocyte globulin; CMV ‐ cytomegalovirus; PTLD ‐ post‐transplant lymphoproliferative disease </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Assessment of harm in non‐randomised controlled studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/full#CD008927-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008927-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Induction versus no induction</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.67, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Acute rejection grade II or higher <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.33, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.97, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.18, 10.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 CMV infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.73, 1.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Bronchiolitis obliterans syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.51, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Post‐transplantation lymphoproliferative disease (PTLD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Induction versus no induction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008927-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Polyclonal antibody versus no induction</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.68, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 ALG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.59, 3.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Rabbit ATG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.63, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Acute rejection grade II or higher <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.30, 1.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 ALG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.18, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Rabbit ATG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.25, 3.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Rabbit ATG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.97, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 ALG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.91, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Rabbit ATG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.3 [0.73, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 ALG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.23, 8.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 CMV infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Rabbit ATG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.77, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Bronchiolitis obliterans syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.55, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 ALG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.55, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Rabbit ATG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.47, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Post‐transplantation lymphoproliferative disease (PTLD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Rabbit ATG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Rabbit ATG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Polyclonal antibody versus no induction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008927-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Interleukin‐2 receptor antagonist versus no induction</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Acute rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 CMV infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Bronchiolitis obliterans syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Interleukin‐2 receptor antagonist versus no induction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008927-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Polyclonal antibody versus muromonab‐CD3</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Horse ATG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Horse ATG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Bronchiolitis obliterans syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Horse ATG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Post‐transplantation lymphoproliferative disease (PTLD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Horse ATG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Polyclonal antibody versus muromonab‐CD3</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008927-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Polyclonal antibody versus interleukin‐2 receptor antagonist</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.54, 3.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Basiliximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.02, 8.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.58, 4.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Acute rejection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.94, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Basiliximab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 CMV infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.17, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Bronchiolitis obliterans syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.42, 6.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Post‐transplantation lymphoproliferative disease (PTLD) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Daclizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Polyclonal antibody versus interleukin‐2 receptor antagonist</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008927.pub2/references#CD008927-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008927.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008927-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008927-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008927-note-0001">Français</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008927\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008927\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008927\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008927\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008927\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008927\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008927\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008927\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008927\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008927\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008927\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008927\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008927\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008927\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008927\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008927\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008927\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008927\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008927.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008927.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008927.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008927.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008927.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724448541"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008927.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724448545"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008927.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e63150d62f3fd',t:'MTc0MDcyNDQ0OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 